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Menstrual disorders present a considerable clinical challenge,
accounting for 10% of referrals to the Gynaecology Out Patient
Department. In the majority of cases no organic cause can be
found, and there has been increasing evidence that local uterine
factors may play an important part in the mechanism controlling
menstruation. It has been shown that excessive menstrual bleeding
is associated with changes in endometrial prostaglandin production,
with the degree of blood loss determined by the relative synthesis
of prostaglandins with vasoconstrictory properties on the one hand
(PGFpx) as opposed to those with vasodilatory properties (PGE2,
PGI2) on the other. Additionally, the interaction between
endometrium and Myometrium has been studied, providing evidence
that the endometrium may supply precursor endoperoxide for
myometrial prostacyclin synthesis.
The first section of this thesis has further investigated the role
of the prostaglandins in the pathogenesis of menorrhagia. Of 70
women recruited with a subjective corrplaint of excessive blood
loss, the diagnosis was confirmed objectively in 21 (blood loss >
80 mis per month) . These women were randomised to receive
treatment with one of the recognised medications for menorrhagia
(danazol, mefenamic acid, norethisterone or a
progesterone-impregnated coil) and the effect on both the degree of
blood loss, and endometrial prostaglandin concentration, was
assessed. There was a significant reduction in menstrual blood
loss in those women treated with danazol or the
progesterone-impregnated coil, and in the latter group there was an
associated reduction in endometrial prostaglandin concentrations.
A major clinical application of the prostaglandins has been in the
field of menstrual induction, and the second part of the thesis has
examined the use of a synthetic prostaglandin analogue to interrupt
early pregnancy. The treatment has been as effective as vacuum
aspiration of the uterus, but at the expense of unpleasant
gastro-intestinal side effects. In an attempt to decrease the
incidence of these side effects, a reduced dose of prostaglandin
has been given both in a controlled-release system, and in
combination with the progesterone receptor antagonist, RU 486.
Menstruation has been successfully induced with this combination,
but nausea and vomiting continue to be seen in 30% of cases.
Finally, the return to ovulation following menstrual induction has
been estimated. The median day of ovulation following
prostaglandin administration was 24 days (range 16-32 days), and it
is suggested that a prolonged delay to ovulation, resulting in
asynchrony between the ovarian and menstrual cycles, would present
a significant constraint to the use of the prostaglandins for
menstrual induction on a regular basis.
3.
CHAPTER 1
DYSFUNCTIONAL UTERINE BLEEDING: A ROLE FOR THE PROSTAGLANDINS
4.
"But nothing could easily be found that is more remarkable than the
monthly flux of women. Contact with it turns new wine sour, crops
touched by it became barren, grafts die, seeds in gardens are dried
up, the fruit of trees falls off, the bright surface of mirrors in
which it is merely reflected is dimmed, the edge of steel and the
gleam of ivory are dulled, hives of bees die, even bronze and iron
are at once siezed by rust, and a horrible smell fills the air; to
taste it drives dogs mad and infects their bites with an incurable
poison."
Pliny
Since ancient times menstruation has been very much a taboo
subject, poorly understood and enshrouded in mystery. However,
over the years much interest has been aroused by this monthly
endometrial shedding, partly out of a desire to discover something
of its underlying mechanisms, but also as a result of the vast
clinical problem that disorders of menstruation can present, for it
is estimated that excessive menstrual blood loss may affect up to
20% of women during their reproductive years (Jacobs et al, 1965;
Hallberg et al, 1966).
Heavy menstrual bleeding, or monorrhagia, may be the result of
organic diseases such as endometrial polyps or fibroids, but in the
majority of instances, no such underlying lesion can be found, in
which case the diagnosis of dysfunctional uterine bleeding can be
made (Novak, 1981). In some circumstances, and especially at the
extremes of the reproductive career, this dysfunctional bleeding
may be the result of a disturbance of ovarian function (Fraser et
al, 1973; Van Look et al, 1977), however, in most women with
regular but heavy periods, no impairment of the hypothalamo -
pituitary - ovarian axis can be demonstrated (Haynes et al, 1979).
In consequence, much attention has focussed on the endometrium
itself, for it is possible that local factors may play an important
part in the mechanisms controlling menstruation and its disorders.
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In the 1914 Hunterian Lecture to the Royal College of Surgeons,
Beckwith Whitehouse discussed "some of the older views upon uterine
bleeding based principally upon clinical observation, in the light
of that more exact knowledge which scientific study and laboratory
experiment have placed at our disposal". He described the
phenomenon of fibrinolysis of menstrual blood within the uterine
cavity, and demonstrated an increase in thrombolysis at the time of
menstruation itself. In addition he reported confirmation of Blair
Bell's observations on the production of myometrial contractions by
the injection of uterine secretions, and proposed that "a portion
of the uterine secretion is resorbed and serves as a direct
stimulus to uterine contraction, thus diminishing the amount of
blood flowing to the endometrium."
Although a haemostatic role for uterine contractility would seem
unlikely in the non-pregnant state, the importance of an active
endometrial principle in the mechanism of menstruation has received
support. In his classical experiments observing the growth and
degeneration of endometrial explants in the anterior chamber of the
eye of the monkey, Markee (1940) observed that the onset of
menstruation was characterised by intense vasoconstriction of the
spiral arterioles, with accompanying vasodilatation of the
surrounding iridal vessels, and he suggested that these vascular
changes could be effected by "some agent elaborated by the
degenerating endometrium."
Six years previously, von Euler (1934) had demonstrated a plain
muscle stimulating substance from the male accessory genital glands
which he had termed "prostaglandin". However it was not until 1957
that Pickles reported a similar finding in menstrual fluid, and the
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subsequent confirmation of the presence of the prostaglandins E2
and F2cxin both menstrual fluid and endometrium (Pickles et al,
1965) not only revealed the nature of the menstrual stimulant, but
also provided a potential candidate for Markee's vasoactive
endometrial agent.
Much data has now accumulated suggesting a role for the
prostaglandins (PGs) in the pathogenesis of monorrhagia, but before
discussing this further it is appropriate to consider the PGs
themselves in more detail.
The Prostaglandins
The principle biosynthetic pathways of the PGs are outlined in
figure 1. The PGs themselves are not stored in tissues (Bito,
1975), but are synthesised "on demand" from precursor arachidonic
acid. This in turn is released from phosphatidyl - choline in cell
membrane phospholipids by phospholipase A2, or from
phosphatidyl-inositol by phospholipase C (Flower, 1980) .
Thereafter metabolism usually occurs via the cyclooxygenase pathway
to produce the cyclic endoperoxides, PGG2 and PGH2, or via the
lipoxygenase pathway towards leukotriene synthesis. The cyclic
endoperoxides are unstable intermediates, and are therefore rapidly
converted to either the classical primary PGs (e.g. PGD2, FGE2,
PGF2oc ) , or via thromboxane or prostacyclin synthetase to
thromboxane (TX) A2 and prostacyclin (PGI2) respectively. The
latter 2 compounds have half lives of 40 seconds and 3 minutes
(although that of FGI2 can be extended to 6-12 minutes in blood
or autologous cell-free plasma - Orchard and Robinson, 1981), and













The primary PGs are also labile, being almost completely removed
from the circulation on a single passage through the lungs, and are
metabolised to more stable entities with little pharmacological
activity.
The physiological response following activation of the arachidonic
acid cascade is dependent on the relative synthesis of these
various PGs, which have different effects on different tissues.
Pertinent to the reproductive system are their vascular and
muscle-stimulating properties. Of the cyclooxygenase products,
TXA2 is a potent vasoconstrictor and stimulant of platelet
aggregation, as opposed to PGI2, which is a vasodilator and the
most potent inhibitor of platelet aggregation yet discovered
(Gryglewski et al, 1976). Indeed, a specific control mechanism
appears to exist between these two PGs in relation to the
equilibrium between the platelet and the blood-vessel wall (Moncada
& Vane, 1978).
PGF2 x has vasoconstrictory properties, and its myometrial -
stimulating action has been implicated in the pathogenesis of
dysmenorrhoea (Pickles et al, 1965; Chan & Hill, 1978; Lumsden et
al, 1983), and in the generation and maintenance of uterine
activity in the pregnant uterus (Csapo et al, 1973a; Brennecke et
al, 1985) . On the other hand, PGE2 possesses vasodilatory
effects (Malik & McGiff, 1976) albeit with one sixth of the potency
of prostacyclin.
Prostaglandin inhibitors
The discovery that aspirin-like drugs inhibit PG biosynthesis by
binding to the cyclooxygenase enzyme (Ferreira et al, 1971; Smith &
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Willis, 1971, Vane, 1971) offered the potential to artificially
manipulate the arachidonic acid cascade. Subsequently a number of
compounds have been developed which inhibit not only the
cyclooxygenase enzyme, but specifically prostacyclin or thromboxane
synthesis (Moncada et al, 1976 and 1977; Tyler et al, 1981).
Inhibition of the cyclooxygenase enzyme by the non-steroidal
anti-inflammatory agents has had the greatest clinical impact, and
the use of one such drug, mefenamic acid, will be discussed in
detail in Chapters 2 and 3. However, it should be noted that these
compounds will not only result in an indiscriminate inhibition of
endoperoxide and other PG synthesis, but that they may also direct
arachidonic acid metabolism towards the lipoxygenase system
(Pakrasi & Dey, 1985).
Uterine prostaglandins
The capacity of the female reproductive tract to synthesise PGs is
considerable, and these compounds appear to play a part not only in
normal physiological processes, such as menstruation, implantation
and labour, but also in various pathological states.
The major endometrial prostanoids are PGE2 and PGF2o< (Pickles
et al, 1965) and their production varies throughout the menstrual
cycle. PG concentrations are low in the proliferative phase, and
increase markedly in the second half of the cycle, but there is
debate as to whether the maximum concentrations occur in the
mid-secretory phase (Maathius & Kelly, 1978), or at the onset of,
and during, menstruation (Downie et al, 1974). The endometrium
also synthesises smaller amounts of FGD2 (Smith et al, 1981a) and
6oxoPGF1 (Rees et al, 1984b; Kelly et al, 1984), though the
powerful pharmacological properties of prostacyclin should be borne
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in mind when considering its possible physiological role in such
low concentrations.
Endometrial thromboxane production appears to be low (unpublished
observations cited in Rees et al, 1984b).
The main product of arachidonic acid metabolism in the myometrium
is 6oxoPGF1?< (Fenwick et al, 1977; Jones et al, 1977; Abel &
Kelly, 1979). Although the production rate per gramme of tissue is
similar to that in the endometrium itself, total uterine
6oxoPGFj^ synthesis is augmented by the large muscle mass of the
myometrium. Furthermore, there may be an interaction between
endometrium and myometrium, with the former tissue providing
precursor endoperoxide for myometrial PGI2 synthesis (Abel &
Kelly, 1979; Smith et al, 1981b).
In addition to the cyclooxygenase products of the arachidonic acid
cascade, recent evidence has suggested the presence of lipoxygenase
pathways in the uterus (Hahn et al, 1985), with a preponderance of
lipoxygenase activity in the myometrium (Derners et al, 1984).
However Rees et al (1986) have demonstrated a significantly greater
release of the leukotrienes C4, D4 and E4 from endometrium
than from myometrium, and have proposed a cyclical production of
these compounds with a peak in the mid luteal phase. Major
methodological differences will contribute to these conflicting
results - in the former study the monohydroxy acids
5-hydroxyeicosatetraenoic acid (5-HETE) and 12-HEIE were identified
by high pressure liquid chromotography after incubation of
arachidonic acid with human platelets, whereas the latter study
utilised specific leukotriene antibodies for radioimmunoassay.
11.
Prostaglandins in pathological states; prostaglandins and
Menorrhagia
Since Pickles' earlier observations (Pickles 1957; Pickles et al,
1965), increased concentrations of pgf2 ^ and pge2 have been
further demonstrated in the menstrual fluid of women with
dysmenorrhoea (Lumsden et al, 1983; Rees et al, 1984a). The PGs
have also been implicated in the pathogenesis of monorrhagia.
Willman et al (1976) reported an increase in endometrial pge2 and
pgf2 ^ in both the follicular and luteal phases of the menstrual
cycle in women with dysfunctional uterine bleeding, however the
degree of blood loss was not measured (see Chapter 2). More
recently, using the alkaline haematin method to assess menstrual
loss (Hallberg and Nilsson, 1964), Smith et al (1981a and 1982)
have defined abnormalities in endometrial pg synthesis in women
with both ovulatory and anovulatory menorrhagia. In those patients
experiencing regular ovulatory cycles, there was an association
between menstrual blood loss (MBL) and the ratio of pge : pgf2^,
and, in addition, women with a blood loss >90mls had a
significantly greater endometrial concentration of pge than those
individuals with normal menses. It was therefore suggested that
excessive bleeding resulted from a shift in endometrial conversion
of endoperoxide from the vasoconstrictory PGF2PC to the
vasodilator pge2. In persistent proliferative endometrium
however, the abnormality appeared to be an impaired pg synthetic
capacity due to a reduced availability of precursor arachidonic
acid. Again the ratio of the concentrations of pgf2t>c: pge was
inversely related to the degree of MBL, but the concentration of
pgf2c< in persistent proliferative and normal secretory
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endometrium was also signficantly correlated with the degree of
bleeding.
This relationship between PGF2 * and measured MBL, though
apparently inconsistent with the concept of an imbalance between
the vasodilatory and vasoconstrictory PGs, has also been reported
in menstrual fluid on the first day of menses, with an associated
increase in PGE2 on the second day (Rees et al, 1984a). However,
using a superfusion technique, alternative data from the same
laboratory (Rees et al, 1984b) failed to show any correlation at
any stage of the menstrual cycle between MBL and the endometrial
release of PGF2tx, PGE2 or 6oxoPGF-j_o< . Both the difficulties
of measuring tissue PGs and different techniques of measurement
will contribute to such variance in reported data, and this
problem will be discussed in Chapter 3.
Ovarian Control
The influence of the ovarian steroids on the control of uterine PGs
should also be addressed. The cyclical nature of endometrial PG
production has already been mentioned, and it has been suggested
that the increased PG production in the luteal phase may be a
direct result of the action of progesterone. An apparent paradox
exists though, for progesterone itself appears to inhibit both PG
release in tissue culture (Abel and Baird, 1980; Tsang and Ooi,
1982; Gurpide et al, 1986), and also PG appearance in the
utero-ovarian vein of the guinea-pig (Blatchley and Poyser, 1974).
A period of progesterone priming though, followed by estradiol
stimulation appears to constitute the optimum conditions for
PGF2k synthesis (Abel and Baird, 1980), however this view has
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recently been challenged by Schatz et al (1985), who have suggested
that the removal of an inhibitory influence during the isolation
and culture of endometrial glands may account for the differences
in cited results. In summary, it may be that progesterone has a
role in facilitating precursor arachidonic acid storage in the
luteal phase, resulting in a given potential for PG synthesis,
which will be unmasked as steroid concentrations fall with
impending menstruation. Such a role could be mediated via an
impairment of phospholipase activity (Wilson et al, 1986).
The observed physiological effects of the PGs are related not only
to the rate of tissue synthesis, but also to the balance between
synthesis and degradation. Although estradiol stimulates
cyclooxygenase activity (Ham, 1975), no specific effect is seen on
PGF2^ metabolism in vitro (Schatz et al, 1985). Progesterone on
the other hand stimulates PG metabolism, which is greatest in the
second half of the cycle (Casey et al, 1980; Abel and Kelly, 1983)
and which can be reduced in vitro using the progesterone receptor
antagonist RU 486 (Kelly et al, 1986b). Furthermore, these
steroidal effects are inter-related, as estradiol induces
progesterone receptors in the human uterus (Janne et al, 1975),
whereas progesterone itself suppresses the estradiol receptor (West
& Brenner, 1985).
The first part of this thesis aims to further investigate the role
of the PGs in the pathogenesis of menorrhagia. Chapter 2 outlines
the definition of a group of women with objectively diagnosed
ovulatory dysfunctional bleeding, and demonstrates the clinical
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effects of four medical treatments (danazol, mefenamic acid,
norethisterone, and a progesterone - impregnated coil) on the
degree of blood loss. In addition, endometrial biopsies have been
obtained to evaluate the relationship between endometrial PGs and
MBL, and to assess whether the four medical treatments are
associated with changes in the pattern of endometrial PG
production. These data are presented in Chapter 3. Finally,




THE OBJECTIVE ASSESSMENT OF MENSTRUAL BIOOD LOSS
16.
The assessment of menstrual blood loss must be based on objective
measurement. A subjective account of the degree of blood loss,
either in terms of the number of days bleeding or the amount of
sanitary protection required is inadequate to diagnose menorrhagia,
for it has been shown that up to 50% of women complaining of heavy
periods have a measured blood loss within normal limits (Fraser et
al, 1981; Dockeray et al, 1986).
Many methods have been used to assess MBL objectively including the
weighing of sanitary towels (Pendergrass et al, 1984), and the
measurement of haem iron by absorption spectrophotometry (Cole et
al, 1971). However the most popular method has been to determine
the concentration of haemoglobin in the menstrual effluent by
converting it to an alkaline haematin derivative which can be
quantified colorometrically (Hallberg & Nilsson, 1964; Newton et
al, 1977).
Using the alkaline haematin method, the mean monthly blood loss in
one large population study (n=476) was 43 mis (Hallberg et al,
1966). The 95th centile for MBL was 76.4 mis, and 67% of those
women with a blood loss in excess of 80 mis showed evidence of iron
deficiency anaemia. The development of anaemia will depend to a
major extent on the intake of iron, and it has been suggested that
if the monthly MBL exceeds 50-60mls, negative iron balance will
result on an "average" western diet (Rybo, 1966; Smith, 1982). The
upper limit of normal for MBL has therefore been defined as 60-80
mis.
The present study has examined a group of women presenting with a
subjective complaint of menorrhagia. MBL has been measured using a
17.
modification of the alkaline haematin method, and the effects of
medical treatment on the degree of blood loss have been assessed in
those women in whom the diagnosis of heavy menses has been
confirmed.
PATIENTS AND METHODS
70 parous women with a subjective complaint of heavy periods were
recruited from the Gynaecological Out Patient Department of the
Royal Infirmary, Edinburgh. All suffered from dysfunctional
uterine bleeding and had undergone diagnostic curettage to exclude
underlying organic pathology. None of the women were currently
receiving medical treatment for their menorrhagia.
Patients were instructed to collect their sanitary towels/tampons
for 2 cycles in order to assess their blood loss objectively. Each
woman kept a calendar of her menstrual loss, and in addition 26
patients collected early morning urine samples 2 or 3 times weekly
to monitor ovarian function. All patients were specifically asked
to avoid self medication with proprietary preparations,
particularly those containing aspirin or similar agents.
The women were reviewed in the mid luteal phase of the second study
cycle, when those individuals with a mean monthly MBL of <50mls
were excluded from further study (see discussion). Those with a
greater blood loss received treatment with either danazol,
mefenamic acid, norethisterone or a progesterone - impregnated
coil, and they were asked to collect their sanitary protection for
a further 2 cycles (see Chapter 2(ii)).
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Blood was taken for haemoglobin concentration, white cell,platelet,
and reticulocyte count, along with estradiol and progesterone
concentrations, both before the study, and at each follow up
appointment.
Assessment of Menstrual Blood Loss
MBL was assessed objectively using a modification of the alkaline
haematin method (Hallberg & Nilsson, 1964). Soiled pads and
tampons were placed in molar sodium hydroxide and thoroughly
mixed. 24 hours later, an aliquot was taken, and after filtration,
its optical density was measured at 450nm. MBL was then calculated
by comparing this with the optical density of a peripheral blood
sample similarly processed. The diagnosis of menorrhagia was made
if the blood loss exceeded 80 mis per month.
Prior to the study the reliability of the technique had been tested
using sanitary towels to which known amounts of blood had been
added.
Urinary assays
The urinary excretion of total estrogen was measured
fluorometrically (Brown et al, 1968), and pregnanediol was
estimated using gas liquid chromatography (Chamberlain &
Contractor, 1968). Both the total estrogen and the pregnanediol
were then expressed in relation to urinary creatinine (estrogen:
jjgm/gm creatinine, pregnanediol: mg/gm creatinine).
RESULTS
Of the 70 women, 2 became menopausal during the study and a further
3 failed to collect their towels adequately. The results of the
remaining 65 are presented.
19.
The median age was 39 years (range 25-50) and the median height and
weight 159cm (range 146-169) and 64kg (range 49-89) respectively.
Menstrual Blood Loss
The reliability of the alkaline haematin technique is illustrated
in table 2(i)l.




40 40.6 + 0.6
60 61.81 1.5
Table 2(i)l. Validation of the alkaline haematin method. For each
volume of blood added, the amount recovered represents
the mean f standard error of 6 experiments.
Figure 2(i)l demonstrates the range of monthly MEL. The median
loss was 63 mis (range 7-429). In 44 (68%) cases the MBL was <80
mis, and it was <50 mis in 27 (42%).
There was no difference between those women with and without
objectively diagnosed menorrhagia either in terms of their age,
height or weight, or in relation to the duration of menses and
cycle length (table 2(i) 2). Although the median parity of the two
groups was the same (<80 mis - 2 (range 1-4); >80 mis - 2 (range
1-6)), there were only 2 women who had delivered more than 4
children (parity 5+0 and 6+0 respectively), both of whom were in
the heavy blood loss group.
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21
<80mls (39) >80mls (19)
MBL (mis) 39 (10,78) 156 (86,429)
AGE (years) 38 (25,48) 42 (33,50)
DURATION (days) 5 (2,8) 6 (3,9)
CYCLE LENGTH (days) 28 (23,48) 28 (23,38)
Table 2 (i) 2 Menses duration and cycle length in women with
and without objectivily diagnosed menorfhagia.
Data are presented as the median with the range
in paretheses. The results of 7 women with
anovulatory cycles have been excluded.
Endocrine assessment
Serum progesterone was measured in the latter half of the 2nd study
cycle. 7 (11%) women exhibited anovulatory cycles (mid luteal
progesterone concentration <18 nmol/L), and their characteristics
are shown in Table 2(i) 3.
AGE (years) 42 (35,49)
MBL (mis) 31 (7,210)
DURATION (days) 6 (4,9)
CYCLE LENGTH (days) 29 (21,66)
Table 2(i) 3 The menstrual characteristics of 7 women with
anovulatory cycles. The data are presented as the
median with the range in brackets.
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The data from 24 women who collected urine samples to monitor
ovarian function are shown in figure 2(i)2. 2 individuals who
failed to demonstrate a luteal phase rise in pregnanediol excretion
have been excluded from analysis. There was no difference between
those women with or without objectively diagnosed menorfhagia in
terms of the urinary excretion of both total estrogen and
pregnanediol.
Haematoloaical indices
Haemoglobin concentration, white cell, platelet, and reticulocyte
count did not differ between those women with or without heavy
periods. Table 2 (i) 4 shows the median haemoglobin concentration
and platelet count for those women with a blood loss greater than
or less than 80 mis, and for those women with anovulatory cycles.
MBL < 80mls(39) MEL > 80mls(19) ANOVULATORY(7)
Hb (g/dL) 13.3 (9.5,14.8) 12.6 (10.0,15.0) 13.6 (11.0,14.3)
Platelets
(Xl06/ml) 228 (126, 330) 234 (160,446) 224 (175,275)
Table 2fi)4 Haematological indices. Data represent the median,
with the range in brackets (Hb = haemoglobin).
DISCUSSION
In 1904 Hoppe-Seyler et al. used an acid haematin method to measure
MBL in 15 women, 11 of whom were considered to have pathological
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gynaecological disease. In the 4 "normal" cases, the blood loss
ranged from 26-52 mis with an average of 37 mis. Since this time,
many techniques have been employed in an attempt to quantify both
normal and abnormal MBL. Measuring menstrual blood iron in 100
apparently normal women, Barer and Fowler (1936) found an average
loss of 51 mis (range 7-179), and in 50% of women the loss was
between 23 and 68 mis. In addition they noted that the duration of
the period, or the number of "napkins" used, gave only a vague
indication of the actual degree of blood loss itself.
Other methods have been to weigh sanitary towels - which provides
an estimate of total menstrual loss (blood and fluid) if collected
adequately (Pendergrass et al, 1984; Fraser et al, 1985) - or to
measure menstrual iron losing absorption spectrophotometry (Cole et
al, 1971). The latter study assessed blood loss in 348 women in a
Northumberland mining village: the median blood loss of 28 mis
(range 0.1-280) was similar to that of 30 mis cited by Hallberg et
al (1966) in Gottenberg using the alkaline haematin approach
(Hallberg and Nilsson, 1964).
The alkaline haematin method has become the most widely used
technique for MBL assessment (Haynes et al, 1977; Guillebaud et al,
1978). The procedure is accurate, as shown in the present study,
provided the patient is instructed to collect all her menstrual
loss. However it only measures the haemoglobin component of the
menstruum, and although it is this constituent that is relevant in
relation to the development of anaemia, recent studies have
suggested that in normal women the haem element only comprises 36%
of the total menstrual loss (Fraser et al, 1985). This may partly
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explain the discrepancy between measured and perceived loss in the
present and many previous studies (Fraser et al, 1984).
Here, the finding that 68% of the women with a complaint of
menorrhagia had a blood loss <80 mis is in accord with other data
(Fraser et al, 1981; Dockeray et al, 1986). This again reinforces
the necessity for objective assessment in the diagnosis of heavy
blood loss.
As with the Swedish work (Hallberg & Nilsson, 1966) a blood loss of
>80 mis has been required to diagnose menorrhagia. Nevertheless it
was considered appropriate to treat women with a blood loss >50
mis. Firstly, even with strict patient cooperation, the MBL is
likely to be an underestimate. Secondly, the risk of developing
anaemia will gradually increase as the blood loss extends towards
the upper limit of normal, and women should ideally receive
treatment prior to developing frank iron deficiency. Finally, in
21 asymptomatic women presenting for laparoscopic sterilisation in
Edinburgh, no patient had a blood loss >50 mis (Smith, 1982).
89% of the women in the present study showed a luteal phase
increase in serum progesterone concentration compatible with
ovulation, and of the 7 individuals who failed to ovulate, only 2
had a blood loss >80 mis (156 and 210 mis respectively). The
similarity between the endocrine profiles of those women with and
without menorrhagia was seen in figure 2(i) 2, and these data
confirm the results of others (Haynes et al, 1979).
Although menorrhagia is the most common cause of iron deficiency
anaemia (Cohen & Gibor, 1980), in the present work there was no
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difference in the haemoglobin concentration of those women with
heavy periods, compared with those whose blood loss was in the
normal range. Furthermore, there was no compensatory increase in
the reticulocyte count of those women in the heavy blood loss
group. However, the women recruited for study form a biased group,
for those individuals with excessive menses resulting in gross iron
deficiency anaemia are more likely to be treated surgically rather
than to be referred back to the Out Patient Clinic for medical
therapy after their diagnostic curettage. In addition, despite the
normal haemoglobin concentration, there may be differences in the
iron stores between the 2 groups with normal and heavy menses,
though these parameters have not been measured here.
In conclusion, these data confirm the importance of objective
assessment in the interpretation of menstrual abnormalities. The
next section of this Chapter examines the efficacy of medical
treatment in those women with a measured blood loss >50 mis.
27.
CHAPTER 2(ii)
THE OBJECTIVE ASSESSMENT OF MEDICAL TREATMENT FOR MENORRHAGIA
28.
Numerous methods are available for the treatment of heavy MBL
ranging from the combined contraceptive pill (Nilsson & Rybo, 1971)
or norethisterone (Bishop & Almeida, 1960) , to the use of
prostaglandin (Anderson et al, 1976) and fibrinolytic inhibitors
(Ylikorkala & Viinikka, 1983) or the insertion of medicated
intra-uterine devices (Cohen & Gibor, 1983). Although such
treatments are used widely for the management of menstrual
disorders, in many instances neither the original diagnosis, nor
the subsequent response to therapy, have been evaluated
objectively.
The profile of MBL in a group of 65 women complaining of heavy MBL
was shown in figure 2 (i) 1, where 38 (58%) individuals had a blood
loss in excess of 50 mis. The present study has assessed the
effects of medical treatment on 30 of these women.
PATIENTS AND METHODS
30 women with a mean monthly blood loss of > 50 mis were recruited
for further study from the original group described in Chapter
2(i). All had ovulatory menstrual cycles.
They were randomly allocated to receive treatment with danazol
(200mg daily), mefenamic acid (500 mg three times daily during
menses), norethisterone (5mg twice daily from day 15-25 of cycle)
or a progesterone-impregnated intrauterine device (releasing 65 jugm
progesterone daily). Patients were instructed to collect their
soiled sanitary towels for a further two (mefenamic acid) or 3
cycles (danazol, norethisterone and progesterone coil), and were
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reviewed in the mid luteal phase preceding their last study
period. At this stage blood was taken for haemoglobin
concentration, white cell, platelet and reticulocyte count, and
estradiol and progesterone concentrations. In addition some women
underwent endometrial biopsy to assess PG concentrations, and these
data will be presented in Chapter 3.
Assessment of Menstrual Blood Loss
All patients kept a calendar to chart the duration of each period,
and the interval between periods. MBL was objectively assessed
using the alkaline haematin method as previously described.
RESULTS
The characteristics of the 30 women are shown in table 2 (ii) 1.
There were no significant differences between the 4 treatment
groups.
TREATMENT(n) AGE(yrs) HEIGHT (cm) WEIGHT(kg) PARITY
DANAZOL (6) 42(36,50) 157(149,169) 64(52,76) 2(1,6)
MEFENAMIC ACID(8) 40(33,48) 162(149,164) 64(50,70) 4(2,4)
NORETHISTERONE(8) 39(35,46) 164(162,169) 64(52,73) 4(1,4)
PROGESTERONE 40(29,42) 162(145,164) 70(54,89) 2(2,4)
C0IL(8)
Table 2(ii) 1 Patient characteristics. The median value is
expressed with the range in parentheses.
Table 2(ii) 2 shows the blood loss and menstrual cycle data for the
2 control cycles of the 4 treatment groups. There was no
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difference in the number of days bleeding or the interval between
periods, but those women who received danazol had a heavier blood
loss pre-treatment than those women in the mefenamic acid or the
progesterone coil groups.
TREATMENT (n) MBL(mls) DURATION (days) CYCLE LENGTH (days)
DANAZ0L(6) (70,429) 6(3,7) 29(24,31)
MEFENAMIC
ACID(8) a68(61,169) 5(4,7) 28(23,38)
NORETHISTERONE
(8) 94(55,312) 6(4,7) 28(24,30)
PROGESTERONE
C0IL(8) *>71(56,164) 5(4,6) 26(23,30)
Table 2(ii)2 Blood loss and menstrual cycle characterics.
Median values are given with the range in
brackets, aa and bb : p = 0.01
The effects of medical treatment on MBL are presented in Figures
2(ii)l to 2(ii)4. In the danazol, norethisterone and progesterone
coil groups the treatment results represent the mean blood loss of
the last 2 cycles (i.e. cycles 4 and 5), whereas in the mefenamic
acid group the mean loss over cycles 3 and 4 is given. Changes in
blood loss are shown in absolute figures, and as a percentage of
the original blood loss. Treatment with danazol and the
progesterone coil resulted in a significant fall in MBL. There was
no overall improvement in blood loss with either norethisterone or
mefenamic acid - however in the latter group the loss was reduced
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displayed in table 2(ii)3 along with the number of days bleeding
and the cycle length before and after treatment. Apart from a
doubling in the median duration of bleeding after the insertion of
the progesterone coil, there were no other differences between the
groups.
TREATMENT (n) MBL(mls) DURATION(days) CYCLE(days)
DANAZ0L(6) Pre *187(70,429) 6(3,7) 29(24,31)
Post * 54(30,347) 4(2,6) 28(26,29)
MEFENAMIC ACID(8) Pre 68(61,169) 5(4,7) 28(23,38)
Post 51(45,203) 5(4,7) 28(27,36)
NOREIHISTERONE(8) Pre 94(55,312) 6(4,7) 28(24,30)
Post 106(24,216) 5(3,7) 28(26,29)
PROGESTERONE
COIL (8)
Pre ** 71(56,164) ** 5(4,6) 26(23,30)
Post ** 55(31,75) ** 10(7,13) 26(24,37)
Table 2(ii) 3. MBL and menstrual cycle data before (pre) and after
(post) treatment. *p<0.05, **p<0.01.
The median haemoglobin concentration, white cell, platelet and
reticulocyte counts did not differ between the 4 groups
pre-treatment, and no significant changes occurred after treatment
itself.
All 30 women had ovulated in their first 2 cycles, with a urinary
pregnanediol: creatinine ratio > lmg/gm, or a serum progesterone
concentration > 18nmol/L, in the mid luteal phase (5-12 days prior
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to the siobsequent period). In addition those women who had
undergone endometrial biopsy, and in whom sufficient endometrium
had been obtained, showed histological evidence of secretory
activity in keeping with their menstrual dates. Table 2(ii) 4
shows the serum estradiol and progesterone concentrations of the 4
treatment groups in the mid luteal phase of the 4th (mefenamic
acid) or 5th (danazol, norethisterone, progesterone coil) study
cycles. The number of women in each group showing presumptive
evidence of ovulation was 1(20%), 7(88%), 2(29%) and 4(67%) in the
danazol, mefenamic acid, norethisterone and progesterone coil
groups respectively. The occurrence of ovulation did not differ
statistically between the 4 groups (p > 0.05, Fisher exact
probability test).
PATIENT DANAZOL MEFENAMIC NORETHISTERONE PROGESTERONE
ACID COIL
NO E2 P4 E2 P4 E2 P4 E2 P4
1 163 4.6 486 80.4 86 <2.1 471 35.2
2 168 19.5 397 43.2 83 2.6 379 35.4
3 111 <2.1 228 6.6 94 <2.1 463 8.6
4 99 <2.1 401 39.6 101 6.4 187 <2.6
5 167 <2.1 388 20.6 154 33.6 696 39.6
6 - - 312 21.4 232 29.0 542 55.7
7 506 19.7 <70 <2.1 - -
8 826 59.1 - - - -
MEDIAN 163 <2.1 399 30.5 94 2.6 467 35.3
Table 2(ii)4. Endocrine parameters after treatment. Individual
values for serum estradiol (E2: pmol/L) and progesterone
(P4:nmol/l) are given. Samples not obtained between 5 and 12
days prior to the subsequent menstrual period have been excluded.
The histological analysis of the endometrial biopsies is summarised
in table 2(ii) 5. The 6 mefenamic acid-treated women all showed a
histological picture in keeping with their dates (figure 2(ii)5)
whereas this was only true of one woman in the progesterone coil
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group. The remainder of these women showed a mixed picture of
inactive glandular elements with pseudodecidualisation (figure
2 (ii) 6). In the danazol-treated group, the endometrium was scanty;
samples for histological assessment were obtained from 3 women in
only one of whom were secretory changes detected.
VTIENT DANAZOL MEFENAMIC NOREIHISTERONE PROGESTERONE
NO ACID COIL
1 P S ES S
2 S S S P + ES + D
3 P S S I + D
4 N N S P + ES + D
5 N S N N
6 N S ES ES + D
7 N P N
8 S S I
Table 2 (ii)5. Endometrial histology. Reports from
individual patients are summarised (P - proliferative: ES - early
secretory change less advanced than menstrual dates: S - secretory
change in keeping with dates: I - inactive glands:
D-pseudodecidualisation: N - no biopsy obtained or insufficient
tissue for histological assessment).
Finally no patient complained of serious side effects with any form
of treatment, and none chose to withdraw from medical treatment
once enrolled in the study.
DISCUSSION
Using the alkaline haematin method it has been possible to
objectively assess the efficacy of 4 commonly used agents for the
39.
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treatment of Menorrhagia. Although other treatment methods are
available, such as the combined contraceptive pill (Nilsson & Rybo,
1971), fibrinolytic inhibitors (Ylikorkala & Viinikka, 1983) and
ethamsylate (Harrison & Campbell, 1976) , mefenamic acid,
norethisterone and the progesterone-impregnated coil were chosen to
assess their effects on endometrial PG production (see Chapter 3),
and danazol was selected as a treatment method not necessarily
thought to act via changes in endometrial prostanoids.
Each patient acted as her own control, and although treatment was
allocated randomly, this was neither blind, nor placebo
controlled. Previous workers have failed to show a significant
improvement in MBL with placebo (Chimbira et al, 1980), however
between group comparisons in the present study should be
interpreted with caution.
The 4 groups were similar, but the pre-treatment loss in the women
randomised to the danazol group was significantly greater than that
of those women treated with either mefenamic acid or the
progesterone device. Due to the small numbers this was
unavoidable, but the finding should be borne in mind, for it has
been demonstrated that some methods of medical treatment are more
effective with a higher pre-treatment blood loss (Guillebaud et al,
1978). Despite this increased MBL in the danazol group though,
there were no corresponding differences in haematological indices.
All individuals were selected to ensure that they exhibited
ovulatory cycles during the 2 control months. This is of
particular importance when considering the therapeutic effects of
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drugs such as norethisterone, which has been advocated as a logical
treatment method in cases of anovulation to prevent metropathia
haemorrhagica (Bishop & Almeida, 1960). In addition, as the
majority of women with menorfhagia have ovulatory dysfunctional
uterine bleeding (see Chapter 2 (i)), it is pertinent to examine the
effects of treatment on this group specifically.
The MBL after treatment has been calculated as the mean loss of the
3rd and 4th cycles following mefenamic acid, or the 4th and 5th
cycles following the other forms of treatment. This was necessary
to ensure that the "treatment periods" were the result of adequate
drug exposure, for although the PG synthetase inhibitor mefenamic
acid was taken during the 3rd period itself, the administration
method of the other drugs would lead to an expected treatment
effect in the 4th and subsequent periods.
Blood loss was significantly improved by treatment with danazol or
the progesterone coil, with all the women in these groups having a
reduced loss in their treatment cycles. Although the overall loss
did not change in the other 2 groups, there was a wide variation,
with 6(76%) of the mefenamic acid group and 5 (63%) of the
norethisterone group showing some improvement. The interval
between periods was unaffected by treatment, but all 8 women
treated with the medicated coil experienced inter-menstrual
spotting, and the median duration of the period itself was doubled.
The results of the danazol, mefenamic acid and progesterone coil
groups are in accord with previously reported studies. An
improvement in both MBL and haemoglobin concentration was seen
losing danazol 400mg daily (Chimbira et al, 1979) but this was also
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associated with a significant decrease in the duration of bleeding
(7.710.8 days to 3.610.5 days) after 2 months of treatment.
However, this high dose of drug resulted in two of the 18 women
withdrawing from study because of side effects (acne, muscle cramps
and weight gain). Subsequent studies investigating different dose
regimens (400, 200 and 100 mg) confirmed the effectiveness of 200
mg daily with a reduced incidence of side effects (Chimbira et al,
1980). Both the degree of blood loss and the number of days
bleeding were reduced, though as with the present study, there was
no change in cycle length. The mechanism of action of danazol in
menorrhagia appears to be via both an effect on the
hypothalamo-pituitary-ovarian axis and a direct effect at the level
of the endometrium itself. In this work, a luteal phase
progesterone concentration consistent with ovulation was only seen
in 1 of 5 women, which is in keeping with the results of previous
studies using 200mg of the drug daily (Colle and Greenblatt, 1976;
Van Dijk et al, 1979). Ovulation inhibition appears to be less
consistent with lower doses of danazol, however Greenblatt et al
(1974) noted a 94% anovulation rate in 38 of 46 women receiving 100
mg daily, although cyclical menstrual periods continued to occur.
The 25% overall reduction in MBL with mefenamic acid seen in this
study (68 mis to 51 mis - median values) agrees well with the
results of others (Fraser et al, 1981: 28% - Ylikorkala & Viinikka,
1983: 24% - Dockeray et al, 1986: 20%), although earlier work from
Oxford (Anderson et al, 1976) suggested a 50% overall improvement
in MBL in 6 women. Such data have to be interpreted with care in
relation to differing patient characteristics, variations in the
duration and dosage of treatment, differences in the underlying
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cause of the excessive blood loss, and variations in the initial
degree of blood loss itself (Guillebaud et al, 1978; Fraser et al,
1981). In 2 (25%) cases in the present work there was a
deterioration in blood loss of 48%. Such failure to respond to the
cyclooxygenase inhibitor has been noted elsewhere, with 15 (22%)
women in one study showing no objective improvement in MBL with
mefenamic acid (Fraser et al, 1981). It may be that in some
individuals endometrial PGs do not play a major role in the control
of blood loss. Alternatively, the concentration of mefenamic acid
itself may fail to reach adequate levels at its site of action in
some cases - for it has been shown that there is a direct positive
relationship between peripheral mefenamic acid concentrations and
improvements in the degree of MBL (Dockeray et al, 1986).
Furthermore, it is possible that the abnormal bleeding in such
"non-responders" to mefenamic acid could be the result of augmented
leukotriene synthesis following inhibition of the cyclooxygenase
pathway (Hahn et al, 1985; Rees et al, 1986).
Mefenamic acid is thought to act via a local mechanism on uterine
prostanoids, without affecting the hypothalamo-pituitary-ovarian
axis. This will be considered further in Chapter 3, and would be
supported by the endocrine and histological data presented in
tables 2(ii)4 and 2(ii)5.
A significant improvement in blood loss with the
progesterone-impregnated coil has also been reported by others
(Troughbough et al, 1978; Berqvist & Rybo, 1983), and as in the
present case this treatment has been associated with the occurrence
of menstrual spotting and prolongation of the period. This
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disturbance in the menstrual pattern though must be seen balanced
against the advantages of an effective treatment method which
obviates the need for repeated oral drug administration. In
addition the reduced dosage employed for such local therapy should
decrease the incidence of unpleasant systemic side effects.
The main action of the progesterone coil appears to be local, and
most studies have shown endometrial glandular suppression, with
pseudodecidualisation, in the absence of disturbances of the
hypothalamo-pituitary-ovarian axis (Bryant-Greenwood et al, 1977;
Hagenfeldt et al, 1977; Bonnar & Shephard, 1979; Shaw et al,
1981). The present data would support this, with 4 (67%) cases
showing a luteal phase increase in serum progesterone compatible
with ovulation, and with only one of 6 endometrial biopsies
revealing a histological picture in keeping with the menstrual
dates. The wide variation of histological appearances actually
seen though probably reflects the relatively short duration (2-3
months) of coil exposure (Hagenfeldt et al, 1977).
The effects of the treatment of abnormal MBL with norethisterone
have not been objectively assessed previously, although Bishop &
Almeida (1960) did report a subjective improvement in blood loss in
34 of 52 cycles in 13 women with ovulatory dysfunctional bleeding.
Here, there was no consistent effect on MBL, and in only 2 (29%)
cases was there a rise in the mid luteal progesterone concentration
>18nmol/L. However this would not necessarily indicate an
inhibition of ovulation , for Larsson-Cohn et al (1971) have
suggested that gestogen administration itself may cause a defect in
corpus luteum function.
45.
The predominantly secretory change seen in the endometrial biopsies
could be the result of either ovulation, or a direct effect of the
gestogen on the endometrium.
Along with mefenamic acid, norethisterone is used widely for the
medical treatment of menorrhagia; the results of the present study




THE RELATIONSHIP BETWEEN ENDOMETRIAL PROSTAGLANDINS
AND MENSTRUAL BIOOD LOSS, and
THE EFFECTS OF MEDICAL TREATMENT FOR MENORRHAGIA
ON ENDOMETRIAL PROSTAGLANDIN CONCENTRATIONS
47.
The suggested relationship between endometrial prostaglandin
concentrations and the degree of MBL outlined in Chapter 1 will now
be examined in more detail. In addition the effects on endometrial
PG synthesis of the four medical treatments for menorrhagia
described in Chapter 2 will be assessed. As stated, these drugs
were chosen to observe, (i) the effect of PG synthetase inhibition
(mefenamic acid) on endometrial prostanoid production, (ii) the
influence of both natural progesterone (progesterone-impregnated
coil) and the synthetic gestogen, norethisterone, on endometrial
PGs, and (iii) the actions, if any, of another agent (danazol),
which, though effective as a treatment for menorrhagia is not
thought to act via the arachidonic acid cascade.
PATIENTS AND METHODS
The objective assessment of menorrhagia in 70 women with a
subjective complaint of heavy menses has been described in Chapter
2. Of these, 34 individuals with ovulatory cycles agreed to
undergo endometrial biopsies in the mid-luteal phase of their
second study cycle. 30 women with a measured blood loss >50 mis
were subsequently treated with one of the four medical therapies,
and a further biopsy was obtained in the mid-luteal phase of the
second or third treatment cycle (figure 3.1).
Endometrial biopsies were taken using a Sharman curette without
anaesthesia.
Tissue Collection and prostaglandin measurement






2 \ ,3 A I
49
Laboratories, U.K.). After transport to the laboratory within 5
minutes, the tissue was blotted dry on a gauze swab, weighed, and
immediately placed in ice-cold ethanol. The tissue was then
homogenised using a polytron homogeniser, and centrifuged at 1500g
for 10 minutes at 4°C. The supernatant was aspirated and dried
under nitrogen.
Samples were oximated overnight at 20°C and prostaglandin
concentrations were determined using radioimmunoassay with specific
antisera raised against PG methyloximes (Mox) (Kelly et al,
1986a). Separation of free and bound moieties was effected using
polyethylene glycol 6000. Cross-reactivities, determined by the
amount of PG that caused 50% inhibition of binding of the
appropriately-labelled PG were as follows: PGF2 ^ antiserum with
PGF1(x , 7.2%; PGF31><r , 2.9%; PGF2J3, 3.5%; PGE2, 1.1%;
6oxoPGF1P< ,1.1%; 13,14 dihydroPGF2^ , 1.0%; all other PGs
tested, <0.2%: PGE2(Mox) antiserum with PGEj, 53%; PGE3,
31%; PG^, 0.2%; 15 oxo PGE2, 0.25%; 20-hydroxyPGE2, 3.7%;
8-iso PGE2, 2.9%: 6oxoPGF1(x- (Mox) antiserum with 13,14 dihydro
6oxoPGFlc< , 13.3%; OoxoPGEj, 9.1%; 6,15 dioxo PGFjk , 0.25%;
13,14 dihydro FGF2x, 0.23%; all other PGs tested, <0.2%. Due to
the cross reactivity of PGE2 with other PGs, the value for the
concentration of PGE subsequently quoted will potentially include
prostaglandin from the 1,2 (and 3) series.
The assay sensitivity (defined as the amount of PG distinguishable
from zero with 95% confidence limits) was 2pg. The inter-and
intra-assay coefficiants of variation for 6oxoPGF1Cx , PGE and
PGF2^ were 9% and 7%, 13% and 12%, and 14% and 11% respectively




In 5 cases, following the aspiration of the supernatant during the
PG extraction, the residual pellet was resuspended in ethanol and
re-centrifuged 3 times, to assess the efficiency of the extraction
technique.
ii) Representative studies
Endometrium was obtained at diagnostic curettage from 5 women with
non malignant disease from 3 different areas of the uterus (fundus,
anterior and posterior walls). PG concentrations were assessed as
already described to determine the representative nature of
isolated endometrial biopsies.
Endometrial dating
In all experiments, a portion of endometrium was placed in formol
saline for histological dating (Noyes et al, 1950).
RESULTS
Resuspension studies
The median (range) percentage PG recovery with the initial ethanol
extraction was 91% (81,85), 84% (83,92) and 96% (81,97) for
6oxoPGF1X/ PGE and PGF2 * respectively (n = 5).
Representative studies
Hie median (range) coefficient of variation for the 3 endometrial
biopsy specimens was as follows: 6oxoPGF-j_<x - 16% (7,22); PGE-15%
(9,18), and PGF2K-16% (11,18); n = 5.
Endometrial prostaglandin concentrations and menstrual blood loss
The relationship between endometrial PG concentrations and measured
MBL is shown in figures 3.2 and 3.3. There was a wide range of
observed endometrial prostanoid concentrations. In those women
with a blood loss of <50 mis (34 mis (range 18,40)- n = 7) the
endometrial concentrations of PGE, PGF2pc and "total PG"
(PGE+PGF2+6oxoPGF1p<') were less than those in the endometrium of
women with heavy menses (MBL 98mls (range 55, 432)- n = 27). The
concentrations of PGE and PGF2 « did not differ in either group of
women, but although the concentration of 6oxoPGFlt< was
significantly less than that of PGE or PGF2 in those women with
heavy menses (MBL >50mls), there was no difference between the
endometrial concentrations of the 3 PGs in those women with a blood
loss of <50 mis.
If the results are analysed comparing women with a blood loss of
greater or less than 80 mis, a similar pattern emerges. Again the
endometrial concentrations of PGE and PGF2 ^ did not differ in
either group of women, however there was no significant increase in
PGF2c^ in those women with heavy menses (MBL = 152 mis (86,432), n
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(18,78), n = 18). In both groups of women the concentration of
6oxoPGFlP< was significantly less than that of PGE or PGF2 K.
These data are summarised numerically in table 3.1.
<50mls(7) >50mls(27)
































Table 3.1 The relationship between menstrual blood loss (MBL)
and endometrial PG concentrations (pg/mg) for women with a blood
loss greater or less than 50 mis (I), or 80 mis (II) respectively.
All data represent the median (range). Between group statistical
analysis is represented in the central column. Asterisks refer to
statistical differences between prostaglandin concentrations in any
one group of women (* - p<0.01: ** - p<0.002: *** - pcO.001).
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The effects of medical treatment on endometrial prostaglandin
concentrations
The clinical response to danazol, mefenamic acid, norethisterone
and the progesterone-impregnated coil has been described in Chapter
2. Of the 30 women, satisfactory biopsies were obtained both
before and after treatment on 23 occasions. The changes in MBL and
endometrial PGs are presented in Table 3.2 and figures 3.4-3.7.
Danazol
MBL was improved in all four cases in which endometrial biopsies
were obtained, however the effects on endometrial PG production are
difficult to interpret due to the small number of cases. Biopsies
were attempted in the remaining two patients, however, the degree
of endometrial atrophy prevented adequate tissue sampling.
Mefenamic acid
There was an overall improvement in the degree of MBL, but this was
not associated with changes in endometrial PG concentrations. Of
the 8 women treated with mefenamic acid, one declined to undergo
biopsy post-treatment, and in another, inadequate tissue was
obtained.
Progesterone-impregnated coil
The improvement in MBL in all 7 cases was associated with a
significant reduction in PGE, PGF2 ^ and "total" endometrial PG
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Norethisterone
There were no significant changes in endometrial PG concentrations
after norethisterone therapy. 2 patients failed to attend for
their second biopsies - MBL had improved following treatment in one
case, and worsened in the other.
DISCUSSION
The conflict in the reported association between endometrial PGs
and menorrhagia has been pointed out in Chapter 1. Many studies
have shown a relationship between the vasodilatory PGE and the
degree of bleeding (Smith et al, 1981a; Baird et al, 1981), though
an association between PGF2 c< and objectively measured blood loss
has also been proposed (Smith et al, 1982; Rees et al, 1984a).
The present study has again demonstrated a relationship between PGE
and blood loss, however, it has also shown an association between
MBL and "total" PG, or PGF2 c< , dependent on the criteria used to
define the menorrhagic population.
Numerous reasons could account for the apparent inconsistency in
cited data. Firstly, the measurement of the PGs themselves is
fraught with difficulty. The compounds are produced readily when
tissue is subjected to trauma, and so the very process of obtaining
an endometrial biopsy will stimulate PG production (Green, 1979).
It follows that care must be taken in interpreting studies, for the
spurious elevation of PGs resulting from trauma during tissue
collection does not necessarily reflect the in-vivo situation.
Specimens obtained by biopsy and subjected to homogenisation
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probably reveal the potential of the tissue to produce PGs on
maximal stimulation. Such a measurement is of relevance in the
assessment of PGs and menstruation, for it is likely that the
influence of the PGs is actually exerted at the onset and during
menstruation itself, following activation of the arachidonic acid
cascade by the trauma of ischaemia and necrosis.
Alternatively the PGs have been measured using incubation systems
(eg. with radio-1abe11ed arachidonic acid) or
superfusion/perifusion techniques. The use of the former method to
obtain quantitative data has been questioned, as the variable
arachidonic acid content of different tissues can have a marked
effect on labelled-substrate metabolism (Dimov et al, 1983).
Superfusion/perifus ion techniques have been advocated in that a
steady state is reached, presumably after the initial
trauma-induced PG production has subsided (Liggins et al, 1980;
Peek et al, 1985). However, it is mandatory to ensure tissue
viability, for it may be that the steady state merely reflects the
release of PGs from slowly dying tissues in the in-vitro
situation. The method of PG assessment will affect the observed
relationships with MBL, and Rees et al (1984b) using a superfus ion
technique, have failed to show any association between endometrial
PGs and measured blood loss.
Comparison between studies must also take account of the actual
method of PG measurement employed. The primary PGs are labile and
are rapidly metabolised to more stable compounds. Metabolites such
as 13,14 dihydro 15keto PGF2p< (PGFM2) and 13,14 dihydro 15keto
PGE2 (PGEM2) can be measured (Demers et al, 1983), and although
not performed in the present work, this can provide additional
information on specific prostanoid activity. PG metabolism can
63.
also occur during assay, extraction, and sample storage, and
attempts to overcame this have led to the use of bicyclo compounds
(Granstram, et al, 1982) or methyl oxime derivatives, as in the
present study (Kelly & Abel, 1983; Kelly et al, 1986a), prior to
assay.
In addition, the wide variation in "normal" PG concentrations, the
in-built variation (inter and intra) in the assay systems
themselves, and other variables such as the true representative
nature of the specimens obtained or the accuracy of the extraction
procedures will all contribute to differences in reported data.
Finally, the precise relationship between the PGs and different
study populations (i.e. women "with" and "without" menorrhagia)
will depend upon the actual criteria used to define the study
population itself.
Although the term "total" PG here has not included other
arachidonic acid metabolites such as PGD2 or TXA2, the PGs E,
F2 p< and 60X0F2« are thought to be the major prostanoid products
of the endometrium. The suggested association between total
endometrial PG and menstrual loss would account for the improvement
in blood loss following the indiscriminate inhibition of both
vasodilatory and vasoconstrictory PGs after cyclooxygenase blockade
(Anderson et al, 1976). It would agree with the finding of
increased PGF2 ^ and PGE2 in the menstrual fluid of menorrhagic
women (Rees et al, 1984a). In addition, Kelly et al (1984) have
reported an increased availability of endometrial precursor
arachidonic acid (and therefore presumably a potential increase in
PGs) in women with heavy periods.
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The synthesis of endometrial PGs is represented in figure 4.3
(page 78). An increased availability of arachidonic acid would
result in an increased availability of the cyclic endoperoxides
PGG2 and PGH2. These in turn will lead to an increased
synthesis of the primary PGs, mainly PGE2 and FGF2k . As the
conversion to PGE2 can occur both via the isomerase and
non-enzymatically, one consequence of an increased precursor
endoperoxide load could be an increase in the PGE2: PGF2 K ratio
(Smith et al, 1981a and 1982), which would depend on the saturation
level of the PGF reductase enzyme.
The Effects of medical treatment for menorrhacria
Irrespective of the small number of cases, no consistent effect was
seen on endometrial PG concentrations after treatment with danazol,
despite a marked improvement in the degree of blood loss. Major
actions of danazol include binding to and activation of androgen
receptors, displacement of testosterone from sex hormone binding
globulin, and a decrease in the hepatic synthesis of this protein.
These actions increase testosterone concentrations and subsequently
stimulate androgen receptor-mediated effects in the endometrium
(Dmowski, 1979; Tseng et al, 1982; Bevan et al, 1984). The
improved blood loss may therefore be related to a reduction in
endometrial mass, which would be supported by the inability to
obtain endometrial biopsies in 2 of the 6 women under investigation
here.
Mefenamic acid, on the other hand, is known to act mainly as a
cyclooxygenase inhibitor. Nevertheless, no effect was seen on
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endometrial PG concentrations in the present study. However, it
should be noted that the drug was taken for the first 5 days of
menses, and the biopsies were obtained in the mid-luteal phase some
21~3 weeks later - it is perhaps not surprising, therefore, that no
inhibition of the arachidonic acid cascade was seen. Previously
cited data on the endometrial effects of orally administered PG
synthetase inhibitors are conflicting. Shapiro & Haning (1983)
observed no effect on endometrial PGF2 x concentrations during the
mid luteal phase after ibuprofen ingestion, but showed a
significant decrease in the PG when biopsies were taken within the
first few hours of menstruation. This could be related to their
much lower concentrations of PGF2« in premenstrual control
endometrium (0.3 pg/mg) compared with that during menstruation (7.0
pg/mg). The clinical efficacy of the drug itself was not assessed.
Using mefenamic acid, Fraser (1983) investigated nine women with
menorrhagia, in 4 of whom treatment had been unsuccessful. In
endometrial biopsies taken within 4 hours of drug administration,
PGE2 and PGF2 ^ concentrations were suppressed in the 5 women
who were classified as treatment successes, but the 4 "treatment
failures" did not exhibit significant prostanoid inhibition. Again
though, this group of women had lower pre-treatment concentrations
of endometrial PGs than the treatment successes. Further studies
are required to clarify this situation.
The use of the progesterone-impregnated coil in the present study
resulted in both a significant improvement in the degree of MBL and
a decrease in the endometrial concentrations of PGE, PGF2 K and
"total" PG. There are varied reports on the effects of
intrauterine devices on endometrial PG production. Saksena &
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Harper (1974) demonstrated an increase in F prostaglandins in the
cornu of rabbit uteri bearing an intrauterine device, but in women,
the main increase was of PGE (Hillier & Kasonde, 1976). However
others (Green & Hagenfeldt, 1975; Scammegna et al, 1978) have
failed to show a consistent change in endometrial prostanoids after
coil insertion. The variance in results is probably related to
methodological differences in PG extraction and measurement, the
difficulty in obtaining a representative endometrial sample in
close proximity to the coil itself, and the varied duration of
intrauterine device usage prior to biopsy. Employing the same
medicated coil as in the present study though, both Troughbough et
al (1978) and Zahradnik et al (1978) noted a reduction in
endometrial PGF2 ^ . It may be that the continuous administration
of progesterone throughout the cycle results in an impairment of
estradiol receptor generation (Shaw et al, 1981; West & Brenner,
1985), which in turn could lead to impaired estradiol-mediated
cyclooxygenase activation, and a decrease in prostaglandin
synthetic capacity. Alternatively, the progesterone may stimulate
PG metabolism (Casey et al, 1980; Abel & Kelly, 1983), thereby
reducing the observed tissue concentrations. Further studies
assessing endometrial steroid receptors or PG metabolite
concentrations are therefore required to test these hypotheses.
Finally, with norethisterone there were no changes in either MBL or
endometrial PG concentrations. It would be pertinent though to
observe the effect of this synthetic gestogen on endometrial PG
production, when administered in the second half of the cycle to





The pattern of prostaglandin production from isolated endometrial
biopsies has been outlined in Chapter 3, however in vivo the
endometrium bears a close relationship, both anatomically and
functionally, with the large muscle mass of the ittyometrium. It is
therefore apposite to examine this relationship in vitro.
In contrast to the endometrium, eoxoPGFj * is the major myometrial
prostanoid in the rat (Fenwick et al, 1977), sheep (Jones et al,
1977) and man (Abel & Kelly, 1979). Whether prostaglandins of the
E and F series are also synthesised in the ittyometrium is less
certain. Although a cyclical variation in both PGE2 and PGF2 «
has been suggested (Vijayakamur, 1980), with a peak myometrial
concentration of both PGs at the time of ovulation, and a secondary
rise in PGE2 content during menstruation, others have failed to
show a significant production of these PGs in uterine muscle (Abel
& Kelly, 1979).
Using broken cell preparations, both with and without incubation
with 14C-labelled arachidonic acid, an interaction between the
endometrium and myometrium has been demonstrated (Abel & Kelly,
1979; Kelly et al, 1984), with an increased production of
eoxoPGF-^c^ when the two uterine tissues are combined.
Furthermore, Smith et al (1981b) reported that myometrial
prostacyclin production could be enhanced on co-incubation of the
muscle with endometrium from women with objectively diagnosed
menorrhagia.
The present work has further investigated the interaction between




Tissue Collection and Prostaglandin Measurement
6 women suffering from benign uterine disease, each with a
subjective complaint of menorrhagia were admitted for abdominal
hysterectomy in the luteal phase of the cycle. At operation,
samples of both endometrium and myometrium were placed in ice-cold
modified 199 medium and transported to the laboratory. After
blotting and weighing both types of tissue, a myometrial homogenate
was prepared in 199 medium (using a Polytron homogeniser), at a
final concentration of 10 mg/ml. Thereafter, small pieces of
endometrium (4.3 mg (1.9, 10.5) - median (range) - n = 48) were
placed in either 1 ml of 199 medium or 1 ml of the myometrial
homogenate, and these samples were incubated at 37°C in a water
bath for 1 hour, with gentle shaking (figure 4.1). 1 ml samples of
myometrial homogenate alone, and control samples of 199 medium were
also processed in similar fashion. Following the incubation, the
pieces of endometrium were removed, and the media were stored at
-20°C until assayed.
Prostaglandin concentrations were measured by radioimmunoassay as
described in Chapter 3.
Endometrial Dating
In all experiments, a portion of endometrium was placed in formol
saline for histological dating. The occurrence of ovulation was
indicated by the presence of secretory endometrium, along with a



















The characteristics of the 6 patients are seen in table 4. All
were in the secretory phase of the cycle, and all showed
biochemical and histological evidence of luteal function. Each of
the women complained of heavy periods, with associated
dysmenorrhoea in two cases, however their menstrual loss was not
assessed objectively.
AGE(yrs) PARITY CYCLE DAY
1 46 3+0 4/28 22
2 43 1+0 8/25 26
3 46 4+2 8/26 25
4 35 4+1 11/24 24
5 40 2+0 7/23 22
6 40 4+0 6/21 17
Table 4. Patient characteristics
Endometrial prostaglandin release, both alone and in combination
with myometrium, is presented in figure 4.2. The value for the
combined incubate has been expressed in pg/mg endometrium per hour,
after correcting for the amount of BG derived from the myometrial
homogenate. Alone, the endometrial production of GoxoPGFj c< was
significantly less than that of either PGF2 K or PGE2. There
was an increase in the production of 6oxoPGF1^ by the endometrium
on co-incubation, however, there was no significant change in the





























The median (range) production of 6oxoPGF1(* , PGF2 ^ and FGE from
the myometrial homogenate alone was 186 pg/mg/hr (54,1109), 87
pg/mg/hr (36,101) and 70 pg/mg/hr (10,239). There was no
statistical difference between the production of these 3
prostanoids.
DISCUSSION
The present work further supports the hypothesis that when
endometrial and myometrial tissues are combined, the endometrium
can supply precursor endoperoxide to the myometrium, where it is
converted primarily to prostacyclin and thence to 6oxoPGF^«.
That it has not been necessary to prepare an endometrial homogenate
to demonstrate this increase in 6oxoPGF1 ^ production would
suggest that the intact endometrium could release precursor
endoperoxide in-vitro. Passage of endoperoxide from the myometrium
to the endometrium would seem unlikely in the absence of an
increase in PGE and PGF2 ^ on co-incubation.
A corresponding reduction in PGE and PGF2 p< production was not
seen on combined incubation, in contrast with previous data (Abel &
Kelly, 1979). This finding could be accounted for by differences
in experimental design, however a decrease in the production of the
PGs E and F2(K, resulting from the diversion of endoperoxide
towards prostacyclin synthesis would only be expected in the face
of a limited supply of precursor endoperoxide itself.
Production of both PGE and PGF20<- was detected in the myometrial
homogenate alone. The capacity of the myometrium to synthesise
these PGs is debated (Abel & Kelly, 1979; Vijayakamur, 1980),
74.
however, the risk of endometrial contamination must be considered
in the interpretation of such data.
The variable degree by which the 6 oxo PGF-j_ * concentration
increased in the present experiments (by a factor of 1.3 to 6.7
times), might have been related to the level of menstrual blood
loss. However, in view of the inadequacies of the subjective
assessment of MBL (Chapter 2), future studies recruiting women with
objectively assessed periods would be necessary to test this
further.
In conclusion, the presented work illustrates that an interaction
between endometrial and myometrial prostaglandin production is
possible, and that precursor endoperoxide can be released from
intact endometrium. Although such in vitro data do not necessarily
prove that this mechanism exists in vivo. the diversion of
precursor endoperoxide towards myometrial prostacyclin production
could have important implications in the pathogenesis of
menorrhagia.
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PROSTAGLANDINS and MENSTRUATION: CONCLUSION
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How can the data from the foregoing chapters be summarised in an
overall plan explaining the role of the PGs in the mechanism of
menstruation, and what is its clinical significance?
The proposed interrelationship between PGs and the uterine
vasculature is schematically represented in figure 4.3. It is
likely that the PGs regulate the degree of blood loss, and that in
vivo this occurs at the time of menstruation itself. The potential
for PG production at menstruation is dependent on the actions of
estradiol and progesterone to induce cyclooxygenase activity and
facilitate arachidonic acid storage respectively. Whether the PGs
are directly involved in the physiological initiation of
menstruation is unclear, though bleeding can be induced by these
compounds (Wiqvist, 1971), and PGF2(x could be the
vasoconstrictive agent seen by Markee (1942) at the onset of
menstruation in his experimental model. However, once the process
has begun, the resultant ischaemic necrosis of the endometrium will
lead to activation of the arachidonic acid cascade. The presented
data suggest that the degree of menstrual blood loss may be related
to the subsequent production of PGs. The observations supporting a
relationship between total PG and the amount of bleeding have been
summarised in Chapter 3, and an increase in prostanoid precursor
load will result in not only an increase in total PG and an
increase in the PGE : PGF2p< ratio, but also in an increased
production of PGI2, both in the endometrium, and in the large
muscle mass of the myometrium (Chapter 4). Although synthesised in
small amounts per gramme of tissue compared with the other primary
PGs, the overall myometrial production of prostacyclin will be
























activity, this compound could contribute significantly to the
degree of blood loss.
The prostaglandins though are not the only agents that may play a
part in the local control of menstrual bleeding. In particular it
has been suggested that there may be an increased activation of the
fibrinolytic system in the endometrium of women with heavy periods
(Bonnar et al, 1983), and such an abnormality is upheld by the
successful use of fibrinolytic inhibitors to improve MBL
(Ylikorkala & Viinikka, 1983). In addition, interactions may occur
between both the PGs and the fibrinolytic system, and other
endometrial products such as prolactin (Healy & Cameron, 1987).
A better understanding of the mechanism underlying menorrhagia
should lead to a more discerning approach to the clinical
management of abnormal menses. The significant morbidity
attributed to disorders of menstruation has already been mentioned
(Chapter 1) , and in addition the pitfalls in the subjective
diagnosis of these disorders have been demonstrated (Chapter 2).
Surely there is now sufficient data to indicate the necessity for
objective assessment prior to subjecting women to major surgery as
a treatment option?
Improved knowledge of the pathogenesis of menorrhagia should also
lead to advances in the availability of medical treatments for
heavy menses. Alternative approaches to PG inhibition could be via
phospholipase inactivation (Mitchell et al, 1977). Furthermore it
is likely that systemic side effects could be reduced by
considering a variety of local therapies, such as medicated
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intra-uterine devices incorporating prostaglandin or fibrinolytic
inhibitors (Tauber et al, 1981).
Matthews EUncan said, "Menstruation is like the red flag outside an
auction sale. It shows that something is going on inside."
(Beckwith Whitehouse, 1914). That something is going on is without




THE THERAPEUTIC APPROACH TO MENSTRUAL INDUCTION
81.
Tlhe role of the prostaglandins in the mechanism of menstruation has
been discussed. Endometrial changes leading to menstrual bleeding
are subsequent to alterations in the pattern of ovarian steroid
production, and the resultant degree of blood loss appears to be
controlled, at least in part, by specific endometrial prostanoids.
However, besides being implicated in the physiological processes
underlying normal menstruation, the isolation of the natural
prostaglandins, and the development of numerous synthetic
analogues, has led to the use of the prostanoids as therapeutic
agents. One clinical application has been the introduction of the
prostaglandins as a medical means of inducing menstruation, and
with the increasing demand for the use of very early abortion as a
method of fertility control, this subject has received much recent
attention.
The second part of this thesis will assess the therapeutic approach
to menstrual induction using one synthetic prostaglandin analogue
(16,16,dimethyl-trans-A2-PGE2 methyl ester: Smith & Baird,
1980) both alone, and in combination with the progesterone receptor
antagonist RU486 (Baulieu, 1985b). These treatments will be
compared with conventional surgical techniques, and consideration
will also be given to the endocrine effects of early pregnancy
interruption on subsequent ovarian function.
Firstly though, it is appropriate to outline the potential clinical
impact of, and the theoretical approach to, menstrual induction.
Since the introduction of the 1967 Abortion Act, pregnancy
termination has became a significant method of fertility control in
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the United Kingdom (Office of Population Censuses and Surveys,
1985). Over 80% of cases present in the first trimester and
surgical evacuation of the uterus remains the most popular
treatment method.
Sumical techniques
Vacuum aspiration was first reported by Simpson in 1863, and at
present flexible plastic cannulae are used most often (Karman &
Potts, 1972). The main side effects associated with this treatment
appear to be related to trauma, to the anaesthetic methods used,
and to bleeding and infection following operation.
The cervix is especially susceptible to trauma during dilatation
(Johnstone et al, 1976), and the necessity for generous dilatation
is related to the gestational age. If less than 56 days have
elapsed since the last menstrual period, minimal dilatation is
required, and this may be achieved by the insertion of
progressively larger plastic cannulae until the appropriately sized
instrument is reached. Trauma to the body of the uterus is
uncommon, especially in early pregnancy, and in over 10,000
reported cases of menstrual regulation the incidence of uterine
perforation has been documented as less than 0.03% (Edelman and
Berger, 1981).
A variety of anaesthetic methods are available for surgical
abortion, and although many centres continue to use general
anaesthesia, local anaesthetic techniques have become increasingly
popular (Meyer, 1983). Methods of vacuum aspiration, as opposed to
dilatation and curettage, besides providing a more complete uterine
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evacuation with less blood loss, have made such local anaesthetic
techniques more feasible, and in very early pregnancies,
particularly in parous women, anaesthesia itself may not be
necessary (Stringer et al, 1975).
Local anaesthetics are usually administered by paracervical block.
Although this avoids the theoretical complications associated with
general anaesthesia, the overall complication rate appears to be
similar with the two techniques (Soderstrom, 1979).
Bleeding usually occurs for about 7-10 days after suction
evacuation, and a similar bleeding pattern has been observed in
prostaglandin - induced abortion, both in terms of the duration of
blood loss, and its measured volume (Smith & Baird, 1980).
The infection rate in early surgically-terminated pregnancies has
been estimated as 1.7% (Edelman & Berger, 1981). However,
stringent follow-up arrangements are necessary (though this is
often difficult in women who request abortions) in order to obtain
a realistic figure. Infection may be related to the completeness
of uterine evacuation, and the incidence of both retained products
and failed abortion is greater in early pregnancy (<42 days
amenorrhoea) than it is later in the first trimester (Hern, 1984;
Nesheim, 1984).
Medical methods of pregnancy interruption
An awareness of these adverse effects, coupled with an increased
demand for the use of early abortion as a routine method of
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fertility regulation, has led to the assessment of medical agents
for menstrual induction.
There are additional advantages to the development of reliable
medical methods for post-conceptional fertility control. The
treatment need only be used vhen required, obviating the need for
the chronic ingestion of synthetic steroids as in the oral
contraceptive pill. Furthermore, medical agents for menstrual
induction offer a favourable alternative to surgery for women
themselves (Rosen et al, 1979). Such treatment also lends itself
to application on a wide scale in developing countries with
considerable population problems, but without the resources to
provide trained surgical personnel (Purandare et al, 1982,*
Aegostina et al, 1984).
The various therapeutic approaches to menstrual induction are shown
in figure 5. C represents the growing conceptus, secreting
chorionic gonadotrophin, which acts to maintain the corpus luteum.
Both the corpus luteum and the trophoblast produce steroids
including progesterone, and this hormone has an essential role in
the development of the embryo and in maintaining uterine quiescence
(Csapo, 1973b).
A variety of agents can be employed to interrupt this equilibrium.
The use of luteolytic compounds such as the GnRH analogues has had
limited application because their action can be overcome by
endogenous hCG (Fraser, 1981). Although uterine PGF21< is the
naturally-occurring luteolytic agent in many species, such as the





appear to be the case in man (Baird, 1985). However, the
prostaglandins have shown promise as menstrual inducers, related to
both their oxytoxic properties (Karim & Filshie, 1970) and their
progesterone - withdrawal effects (Csapo & Pulkkinen, 1979 a & b).
The Prostaglandins
Initially the naturally-occurring prostaglandins were used (Karim,
1971), however, their widespread actions, especially following
systemic administration, resulted in frequent side effects. An
additional problem with the natural compounds was their inherent
lability, and a number of synthetic analogues have now been
produced with increased stability and more specific uterine
activity (Oshima et al, 1978). Analogues of both the E and F
series have been synthesised (MacKenzie et al, 1978; Bygdeman et
al, 1980; Smith and Baird, 1980; Csapo et al 1982), and these
have often been administered in the form of vaginal pessaries.
Although the success rate for abortion induction is high (85-95%),
troublesome gastro-intestinal associated side effects are still
seen in up to 40% of cases despite local methods of drug
administration (Bygdeman & Green, 1979; Bygdeman et al, 1980;
Smith and Baird, 1980). However, care should be taken when
comparing such studies, not only because of the differing uterine
specificity of various analogues, but also because of
inconsistencies in the use of routine prophylactic premedication
(Bygdeman et al, 1980; Foster et al, 1985).
There has been debate regarding the precise mechanism of action of
the PGs in the induction of early abortion. Further evidence has
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accumulated opposing a luteolytic role; Takagi et al (1978) failed
to show a fall in the plasma concentration of 17
hydroxyprogesterone after the administration of 16,16
dimethyl-trans- A 2~PGE1 methyl ester pessaries, and this
finding has been confirmed (Tan et al, 1984). These workers noted
a reduction in plasma estradiol and progesterone concentrations
following therapeutic abortion with 16,16 dimethyl PGE2
p-benzaldehyde semicarbazone ester, and postulated a direct effect
of the prostaglandin on trophoblast steroidogenesis.
That the major role of the prostaglandins is not entirely via
myometrial stimulation was reported in a series of experiments by
Csapo and colleagues (Csapo et al, 1976; Csapo & Pulkkinen, 1979 a
& b), who demonstrated that changes in intrauterine pressure and
cervical dilatation did not occur in unison with the administration
of exogenous prostaglandin. They suggested that the mechanism of
prostaglandin action, the "prostaglandin impact", resulted in
progesterone withdrawal. This would convert the pregnant uterus
from a quiescent to an activated state, following which abortion
could proceed mediated by endogenous (or supplementary exogenous)
prostanoids.
As a means of interrupting early pregnancy, progesterone withdrawal
is highly effective. At early gestations the major progesterone
source is the corpus luteum, and the importance of the corpus
luteum in the maintenance of pregancy was elegantly demonstrated in
luteectomised rabbits using porcine corpus luteum extracts (Allan &
Corner, 1930). Subsequently Csapo and co-workers confirmed these
findings in women, and established that the effects of luteectorny
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on early pregnancy could be reversed by exogenous progesterone
(Csapo et al, 1973b).
The supportive role of progesterone in early pregnancy has been
further demonstrated with the development of relatively specific
"anti-progesterone agents". Progesterone withdrawal using epostane
(a competitive inhibitor of the 36 hydroxy steroid dehydrogenase
enzyme system) appears to sensitise the myometrium to exogenous
oxytocics in early pregnancy (Webster et al, 1985a), and at high
doses it is an effective menstrual inducer itself (Webster et al,
1985b). Alternatively progesterone receptor antagonisation using
RU 48 6 (176-hydroxy-116-(4-dimethylaminophenyl)-17
(prop-l-ynyl)-estra-4,9-dien-3-one) offers the potential for
inducing early abortion with a low incidence of side effects
(Baulieu, 1985a). However, it has been suggested that although the
antigestogens are effective at interrupting pregnancy itself, they
may not induce sufficient uterine activity to expel the products of
conception, and recently an abortion rate approaching 100% has been
demonstrated using RLJ486 treatment followed by one intramuscular
injection of 16-phenoxy-tetranor-PGE2 methyl sulfonlyamide (Swahn
et al, 1985a).
The following chapters discuss the use of both 16,16
dimethyl-trans- A 2~pgei methyl ester (Chapter 6) and KCJ486
(Chapter 7) for the induction of menstruation in early pregnancy.
In addition the effects of menstrual induction on subsequent
ovarian function will be examined (Chapter 8).
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CHAPTER 6
MENSTRUAL INDUCTION USING 16,16,dimethyl-trans-A 2-pGE1
methyl ester : A COMPARISON WITH VACUUM ASPIRATION
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As outlined in Chapter 5, until recently the prostaglandins alone
offered the most promising therapeutic approach to menstrual
induction. However their inherent lability and high incidence of
side effects has limited their therapeutic acceptability.
Although a lower dose of prostaglandin can be used to decrease the
incidence and severity of these side effects, this may lead to a
reduced success rate for abortion itself. One solution would be to
administer the prostaglandin in a controlled-release form, thereby
lessening the "bolus effect" each time that an individual dose of
drug is given. The feasibility of such slow-release systems has
been demonstrated in primate models (Spilman et al, 1984), and
clinical studies have confirmed the efficacy of various devices
both for inducing labour (Embrey et al, 1980), and abortion
(Bygdeman et al, 1984).
The present study has investigated the use of one synthetic
prostaglandin analogue, 16,16 dimethyl-trans- A. 2~PGE1 methyl
ester (figure 6.1) which has been used extensively for the
interruption of pregnancy in both the first (Takagi et al, 1978;
Smith and Baird, 1980) and second trimesters (Cameron and Baird,
1984). The analogue has been used here both in pessary form (lmg
prostaglandin in 0.8 gm. of Witepsol S-52 base), and incorporated
into a controlled-release system (NcNeill and Graham, 1984). Both
methods of treatment have been compared with conventional vacuum
aspiration under general anaethesia.
PATIENTS AND METHODS

















recruited for study. Gestational age was assessed by menstrual
history and clinical examination, with the addition of pelvic
ultrasound where necessary. In all cases, pregnancy was confirmed
with an immunological pregnancy test (Hobson, 1968). Patients with
evidence of abnormal pregnancy or spontaneous abortion were
excluded from study, as were women with medical complications such
as cardiovascular or pulmonary disease, allergy, or epilepsy.
Pregnancy termination was indicated under the 1967 Abortion Act:
local ethical committee approval was granted for the project, and
written informed consent was obtained from each woman prior to
proceeding with treatment.
Once recruited, patients were allocated to the appropriate study
group. The first 60 women were randomised to receive either 16,16
dimethyl-trans- A 2-pgei methyl ester in pessary form, or
vacuum aspiration under general anaesthesia. The remaining 13
individuals were treated with the prostaglandin analogue
administered in a controlled-release device.
Vacuum aspiration
Treatment was performed on an outpatient basis. The cervix was
dilated to a maximum of 8mm, and the uterine cavity was evacuated
using a size 6 or 8 Karman cannula (Karman and Potts, 1972).
Pre-operative cervical priming was not used, but all women received
either 10 U oxytocin (Syntocinon: Sandoz Products, Ltd) or 500pg
ergometrine maleate and 5U oxytocin (Syntometrine: Sandoz Products,
Ltd) immediately prior to, or during the procedure itself.
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16,16 dimethyl-trans-^-PCT^ methyl ester: Pessaries
A single Img pessary was placed in the posterior fornix of the
vagina, and this treatment was repeated every 3 hours until either
the products of conception had been expelled, the frequency or
severity of any side effects became so great as to warrant
cessation of therapy, or until a total of 5 pessaries had been
given.
16,16 dimethvl-trans-A ^-PGEj methyl ester: Controlled-release
device
The device, containing 3mg of 16,16 dimethyl-trans-A 2-PGE-^
methyl ester incorporated into a strip of polyethylene-oxide based
hydrogel (measuring 1.3x10x3mm) was placed in the posterior fornix
of the vagina. It was removed prior to discharge from hospital the
following morning.
After one hour women in both the prostaglandin groups were allowed
to get up, and they remained in hospital for 24 hours.
Prophylactic medication was not prescribed, however analgesics
(paracetamol, lgm; dihydrocodeine 30 mg; or pethidine lOOmg),
antiemetics (cyclizine, 50mg) or other preparations such as
antidiarrhoeal agents, were administered on request. No dietary
restriction was enforced during treatment.
All patients were given appropriate contraceptive advice before
going home, and arrangements were made for follow-up at 1 week, 2
weeks, 4 weeks and fortnightly thereafter, until the onset of the
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next period. Abortion was considered successful at the 2 week
visit if there was minimal vaginal bleeding, the cervix closed, the
uterus was normal in size, and the pregnancy test indicated that
the concentration of human chorionic gonadotrophin was falling. In




Two women in the vacuum aspiration group were excluded from
analysis, having been found to have pregnancies of greater than 56
days amenorrhoea. The characteristics of the remaining women are
shown in table 6.1. There were no major differences between the
treatment groups.
V.A. (28) PG:PESSARY(30) PG: DEVICE(13)
AGE (years) 23,(19,39) 22(18,38) 21(16,45)
HEIGHT (cm) 168(160,180) 168(154,179) 165(155,168)
WEIGHT (kg) 59(52,67) 55(57,79) 58(56,73)
PARITY >28W 5(18%) 5(17%) 4(31%)
<28W 5(18%)* 4(13%) 1(8%)*
GESTATION (days) 49(34,56) 49(33,56) 52(43,56)
Table 6.1 Patient characteristics. The parity, both greater
than and less than 28 weeks is expressed as the number
of parous women with the percentage in parentheses.
Other figures represent the median (range). (V.A. -
vacuum aspiration; PG: pessary - prostaglandin
analogue in pessary form; PG: device - prostaglandin
analogue in slow release form).*p= 0.02.
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Vacuum aspiration
All 28 women received outpatient treatment as planned, without
complication. Blood loss was not measured objectively, but in no
case was transfusion or overnight observation required.
Prostaglandin
28(93%) women received the maximum 5xlmg pessaries. The other 2
individuals in the pessary group aborted gestational sacs after
receiving the 4th pessary, and treatment was therefore
discontinued.
All patients experienced crampy period-like pain of varying
severity. The pain began after 240 minutes (median) in both the
pessary and device group, and this was followed by the onset of
bleeding after 507 minutes (range 267,1440) and 390 minutes
(180,985) respectively in the 2 groups. The difference was not
statistically significant.
Analgesic requirements were similar in the 2 groups, as presented
in table 6.2.





Table 6.2 Analgesic requirements. The number of
individuals requiring pain relief is shown, with
the percentage in parentheses. (Oral -
paracetamol lgm or dihydrocodeine 3 0mg;
Parenteral - pethidine lOOmg or diamorphine
5-10mg, both given intramuscularly with cyclizine
50mg).
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Daring treatment 23(77%) women in the pessary group and 9(69%)
individuals in the device group experienced a short lived pyrexia
of 37-38°C. The temperature settled spontaneously, and in no
case was there clinical evidence of sepsis.
There were no serious side effects. Actual blood loss was not
measured, but on no occasion was the subjective loss so great as to
warrant either blood transfusion or emergency uterine evacuation.
However, vomiting and diarrhoea occurred in 7(23%) and 10(33%) of
the pessary group and 2(15%) and 3(23%) of the device group (N.S.,
p>0.05).
Follow up and success
Vaginal bleeding persisted for 7 days (range 1,25), 10 days (1,17)
and 9 days(6,21) in the vacuum aspiration, pessary and device
groups respectively. In these same groups crampy pain occurred
during the first week in 6(32%), 13(43%) and 7(54%) women.
Successful interruption of pregnancy without the need for
supplementary surgical intervention was seen in 27(96%) women in
the vacuum aspiration group, 29(97%) in the pessary group, and in
11(85%) of the women receiving the controlled-release
prostaglandin. The success rate did not differ statistically
between the 3 groups. The fate of those women requiring uterine
evacuation is shown in figure 6.2.
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POSITIVE IPT IPT
2 WEEKS 4 WEEKS
NEG
V.A. 3 f^ NEG
). POS ^ EVACp3
NEG
PG: PESSARY 3 4 >NEG
^EVAC0
PG: DEVICE 2a >NEG
\ ^POS ^ EVAC^
Figure 6.2
Treatment failures. The fate of each individual with
a positive pregnancy test (IPT) 2 weeks following
treatment is shown:
a - one patient had undergone uterine evacuation
(EVAC) prior to the 2 week appointment.
b - curettage revealed necrotic decidua but no
villi. The IPT was weakly positive.
c - uterine evacuation performed at 2 weeks because
of ongoing pregnancy
d - curettage revealed chorionic villi.
(V.A. - vacuum aspiration; PG:pessary - prostaglandin analogue in
pessary form; PG:device - prostaglandin analogue in slow-release
form).
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Table 6.3 details the haemoglobin concentration and white cell
count, taken before treatment, and at the 4 week follow up
appointment.
Hb(g/dl) WCC(xl09/l)
Pre Post Pre Post
V.A. 12.7(11.5,13.9) 13.0(11.7,14.2) 8.1(4.7,12.5) 6.5(4.9,9.4)
PG:
PESSARY 12.6(11.2,14.0) 12.6(11.0,14.1) 7.5(4.9,11.1) 7.1(4.7,12.3)
PG:
DEVICE 12.9(11.1,14.2) 12.8(11.6,13.6) 8.9(4.7,14.7) 6.5(5.2,8.9)
Table 6.3 Haematological parameters. The haemoglobin (Hb)
concentration and white cell count (WCC) are
presented, before treatment (pre) and at the 4 week
follow up (post), as the median (range).
(VA - vacuum aspiration; PG: pessary - prostaglandin
analogue in pessary form; PG: device - prostaglandin
analogue in slow release form).
The subsequent menstrual period occurred after a similar interval
in each group; the median (range) delay to menstruation was 35
days (24,70), 35 days(26,49) and 32 days (24,48) in the vacuum
aspiration, pessary, and device groups respectively. These data
are considered in further detail in Chapter 8 in relation to the
endocrine profile of the first post-abortion cycle.
Finally, the amount of drug administered to each patient in the
controlled-release group was measured by assaying the residual
prostaglandin in the device. This was kindly performed by Mr M C
Hart, Mr P H Leigh and Dr D J Mills of the Analytical Development
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Laboratories, May and Baker Ltd, using high pressure liquid
chromatography. The median dose received was 1.65 mg (range
1.16-1.86 mg), representing a percentage release of 55% (range 39%
- 62%). There was no relationship between the success rate or the
incidence of side effects, and the dose of drug administered.
DISCUSSION
The present work has compared the use of vacuum aspiration with the
administration of 16,16 dimethyl-trans-A2-PGEj methyl ester
both in pessary form, and incorporated into a controlled-release
device in which cross-linking in a strip of polyethylene
oxide-based hydrogel is induced by the use of an aliphatic
isocyanate (Graham and McNeill, 1984; McNeill and Graham, 1984).
On exposure to body fluids, the polymer swells to about three times
its dry volume, at a rate which can be predetermined by the
composition of the matrix. The drug then diffuses out of the
matrix at a zero order rate, over a time period dependent upon the
thickness of the device, the degree of crystallinity of the
polymer, and the actual prostaglandin used. All of the drug is not
released within 24 hours, however measurement of the residual
prostaglandin in the devices themselves indicated a reproducible
release pattern.
The three treatment groups were comparable in terms of patient
characteristics, though only one woman in the smaller device group
had carried a previous pregnancy that failed to reach viability.
Both the success rate and the degree of blood loss in the vacuum
aspiration group were similar to the findings of previous workers
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(Smith and Baird, 1980; Sidhu and Kent, 1984), however the latter
study suggested that bleeding may be reduced by pre-operative
cervical priming with prostaglandin.
There was no difference between the success rate in the vacuum
aspiration group and that of either of the prostaglandin-treated
groups.
Furthermore, the onset of bleeding and pain occurred at the same
time following both techniques of prostaglandin administration. In
addition, although effective abortion was achieved using a reduced
dose of drug, there was no significant difference in the observed
incidence of gastro-intestinal side effects. This high incidence
of prostaglandin-associated gastro-intestinal complications has
been noted by others, losing a variety of doses and analogues
(Bygdeman & Green, 1979) and may reflect the fact that systemic
absorption is necessary to achieve the required therapeutic
effect. However, although diarrhoea is a relatively specific
prostaglandin effect, the occurrence of vomiting may in addition be
a consequence of both the use of opiate analgesics, and of the
pregnant state itself.
Though there was no difference in analgesic requirements between
the two prostaglandin groups, pain relief was required more often
in these women than in a previous group treated with the same PG
analogue (Smith & Baird, 1980). Direct comparison of such studies
should be performed with caution because of differences in the
women themselves, and variance in the interpretation of the
strength of analgesia needed, both on the part of patients and
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nursing staff. Analgesic needs may also be related to the place of
treatment, for pain tolerance is likely to be greater in familiar
surroundings than in the cold clinical setting of the hospital.
In conclusion, the use of 16,16 dimethyl-trans-A 2-PGE1 methyl
ester in either pessary or slow-release form provided an effective,
safe alternative to vacuum aspiration under general anaesthesia,
however the reduced dosage administration in the slow release
device failed to improve the incidence of gastro-intestinal
associated side effects.
It may be that these problems will only be overcame using a
different approach to early pregnancy interception. The studies of
Csapo illustrating the "prostaglandin impact" and the importance of
the removal of progesterone in early abortion have been outlined
(see Chapter 5), and the recent development of the antiprogesterone
agents (Healy and Fraser, 1985) has presented the opportunity to
investigate the role of these compounds as menstrual inducers.




MENSTRUAL INDUCTION USING THE ANTIGESTOGEN RU486
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The anti-progesterone agents offer an alternative approach to
menstrual induction. Clinical studies have already confirmed the
safety of the progesterone-receptor antagonist RU 486, but the low
incidence of complete abortion has been disappointing (Herrmann et
al, 1982; Kovacs et al, 1984). A combined therapy using both RU
486 and prostaglandin may be more effective, and Swahn et al
(1985a) have demonstrated an improved abortion rate losing the
antigestogen followed by a single intramuscular injection of
16-phenoxy-tetranor-PGE2 methyl sulfonylamide.
The present study has further investigated the use of RD 486 for
the interception of early pregnancy both alone and in combination
with gemeprost (16,16 dimethyl-trans- A 2-pgei methyl ester)
vaginal pessaries.
PATIENTS AND METHODS
40 women requesting pregnancy termination under the 1967 Abortion
Act were recruited for study. All were of a gestational age of 56
days amenorrhoea or less, and all fulfilled the inclusion and
exclusion criteria outlined for the comparative study in Chapter 6.
Patients were randomly allocated to the study groups. 20 received
RU486 alone (Figure 7), given orally at a dose of 150 mg daily for
4 days. The remainder were also treated with the same dose of RU
486 for 4 days, but in addition they received lmg of 16,16
dimethyl-trans-A2-PGE1 methyl ester in the form of a vaginal
pessary given 48 hours after commencing the antigestogen.




In-patient management and follow up arrangements were as detailed
in Chapter 6. Any woman not meeting the clinical and endocrine
requirements for a diagnosis of complete abortion at the 2 week
follow up visit underwent uterine evacuation under general
anaesthesia.
Blood loss was objectively assessed in both groups of women using
the alkaline haematin method (Chapter 2).
RESULTS
One woman in the RU486 + FG group had treatment discontinued after
3 6 hours because of side effects prior to receiving any
prostaglandin. She has been excluded from analysis.
There were no differences between the characteristics of the 2
treatment groups (Table 7).
KQ486(20) RU486+PG(19)
AGE (years) 25(17,41) 23(17,38)




Table 7 Patient characteristics. Apart from parity, which
represents the number of parous women with the percentage in
brackets, the data presented show the median and range.
The successful induction of bleeding followed by complete abortion
occurred in 12(60%) women in the RU 486 group, but in 18 (95%) of
those women treated in ccatbination with PG (p=0.01). At uterine
evacuation there was evidence of fetal tissue in all 8 treatment
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failures in the former group, and in 5 cases the fetal heart was
present on ultrasound scanning prior to surgery. The one "failure"
in the HJ486 + PG group underwent curettage 6 weeks after initial
treatment because of persistent mild discharge and an ultrasound
appearance consistent with the presence of minimal debris within
the uterus. Necrotic trophoblastic tissue was demonstrated
histologically at operation.
There were no differences between the two groups in terms of the
onset of crampy abdominal pain or vaginal bleeding. The median
(range) day of onset was 2(0,4) and 3(0,4) for pain, and 3(1,6) and
3(1,4) for bleeding, in the KCJ486 alone and RCJ486 + PG groups
respectively. In addition, the use of analgesics during drug
administration was similar for the 2 treatment methods, with
15(75%) women in the KU486 group and 10(53%) in the EU486 + PG
group requiring no pain relief (N.S. p=0.09). 3(16%) individuals
required parenteral analgesia, all of whom were in the PG treated
group (N.S. p=0.1).
11 (55%) women in the KU486 group and 7(37%) in the EU486 + PG
group complained of nausea during the first 2 days of treatment,
whereas in 2(11%) cases in the latter group this was only noticed
after PG administration. The incidence of nausea in the 2 groups
on the day prior to treatment with RU486 was 58% and 69%
respectively in the 13 women whose data were available for
analysis.
Vomiting occurred in 1(8%) of 13 women prior to treatment with
RCJ486 alone and in 3(33%) of 9 before they received the combined
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therapy. During therapy the number of women with vomiting was
3(15%) and 6(32%) in the KCJ486 alone and HJ486 + PG groups
respectively. There was no significant difference between the two
groups, nor was there any difference before and after treatment in
either group, or in the incidence of vomiting before and after the
administration of PG in the combined treatment group.
Diarrhoea was seen on day 2 in one woman in the KU486 alone group,
and in one woman on day 3 in the RCJ486 + PG group.
24 individuals collected their soiled sanitary protection to assess
blood loss objectively. The median (range) loss was 53(2,227)mls
(n=ll) for the KU486 alone group and 81 (32,222) mis (n=13) for the
combined RCJ486 + PG group (N.S. p>0.05). Five of the 11 patients
in the MJ486 alone group had undergone uterine evacuation for
failure to induce abortion - the median blood loss of the remaining
6 women was 62(45,227) mis.
One patient in the RU486 alone group had uterine evacuation
performed as an emergency because of heavy bleeding 3 days after
the cessation of treatment. The degree of blood loss was not
measured objectively, however she was not clinically shocked and it
was not considered necessary to transfuse her. The patient's
haemoglobin concentrations before treatment, and the day after
operation, were 12.2 and 11.4 g/dl. Blood transfusion was required
though for another woman treated with KU486 alone who bled heavily
following uterine evacuation after treatment failure.
Excluding those women who required operative intervention, bleeding
persisted for 10(5,29) days in the RCJ486 alone group and 11(5,34)
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days in the PG treated women.
Finally, the interval to the subsequent menstrual period was
39(23,64) days and 35(18,48) days in the EU486 and KU486 +PG groups
respectively.
DISCUSSION
The present work has examined the use of EU486 for menstrual
induction both alone and in combination with 16,16 dimethyl-trans-
A 2~PGEj methyl ester pessaries. Such a combined approach has
been advocated on theoretical grounds to improve uterine
contractions (Baulieu, 1985a), and in addition the action of the
antigestogen to sensitise the uterus to oxytocic agents (Swahn et
al, 1985a) should lead to a reduction in the dose of PG required to
induce abortion, with a fall in the incidence of unwanted side
effects. Using various dose regimes of KU486 in combination with
prostaglandin (16-phenoxy-tetranor-PGE2 methyl sulfonylamide), a
complete abortion rate of 100% was seen in 16 women (Swahn et al,
1985a), although a subsequent failure has been reported (Swahn et
al, 1985b).
This study has confirmed the success of combined therapy using a
fixed dose of RU486, and administering Img of synthetic PG in
pessary form after 48 hours. A similar success rate for complete
abortion would be anticipated with this PG alone (see Chapter 6),
but at a dosage of 5 x lmg pessaries over 12 hours. Although the
administration of PG in this form may be more acceptable to the
patient herself than intramuscular injection, the latter route may
be preferred, as vaginal drug absorption can be altered in the
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presence of bleeding. The efficacy of treatment was not impaired
in this study though, where 10(53%) women reported the onset of
bleeding prior to pessary insertion.
Most patients experienced crampy pain during treatment, and there
was no difference between the 2 groups as judged by analgesic
requirements. A similar analgesic usage has been reported
previously using gemeprost pessaries alone (Smith & Baird, 1980),
but more pain relief was required by those 30 women treated with
the same PG in Chapter 6 of this thesis; some form of analgesic
being requested by 25(86%) women as opposed to 9(47%) for the
combined RCJ486 and PG group in the present work - p<0.01. As
previously mentioned care must be taken in comparing such results
due to the varying subjective awareness of pain in different
populations, varying environmental factors, and also to differences
in the perception of analgesic requirements on the part of medical
and nursing staff.
No serious complications were encountered during therapy, although
women in both groups suffered gastro-intestinal associated side
effects. Though some patients failed to provide adequate
pre-treatment data, it appeared that the incidence of nausea and
vomiting did not alter after the commencement of treatment with
RU486, nor was it significantly affected by the subsequent
administration of PG. As outlined in Chapter 6, nausea and
vomiting are commonly seen in early pregnancy, but diarrhoea is a
more specific PG-associated problem - this was only seen in one
case in each treatment group.
RCJ486 administration was discontinued in one woman after 36 hours
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because of severe nausea and vomiting which pre-dated the start of
treatment. She subsequently underwent vacuum aspiration under
general anaesthesia without complication, but this emphasises the
potential problem of oral drug administration to some women in
early pregnancy.
It has been suggested that besides increasing the complete abortion
rate, the effect of RU486 plus PG on uterine contractility may also
reduce the degree of blood loss (Baulieu, 1985b). This was
assessed objectively in the present study; the median values of 52
mis and 81 mis for the 2 groups are comparable with the measured
loss following early abortion with either PG alone or vacuum
aspiration (Smith & Baird, 1980), and are similar to the expected
menstrual loss during a heavy period (Hallberg et al, 1966).
24(61%) individuals actually collected their soiled sanitary
protection, but one woman failed to do so because of a complaint of
heavy bleeding - the loss was not so heavy as to warrant
transfusion or curettage, but her haemoglobin concentration fell
from 12.3 g/dl to 11.6 g/dl between the start of treatment and the
first follow-up appointment. There was no evidence that the
remaining women failed to collect their towels for this reason.
One patient in the RCJ486 alone group suffered acute bleeding
necessitating uterine evacuation 12 hours later. Although the
haemorrhage did not require transfusion, and it settled with bed
rest, such a conservative approach would not have been clinically
acceptable. Previous work has emphasised the potential danger of
excessive bleeding after PU486 treatment (Kovacs et al, 1984),
however blood loss has not been objectively assessed. Subjective
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data on the degree of blood loss between various studies must be
interpreted with caution in the light of the finding that up to 50%
of women with a subjective complaint of menorfhagia will have a
monthly menstrual loss within normal limits (see Chapter 2).
The duration of blood loss was again similar for the 2 treatment
groups, and did not differ from that seen previously with either PG
or surgically-induced early abortion (Chapter 6).
Thus, the antigestogen KU486 provides a safe method for early
abortion, with a low incidence of side effects. When used alone,
there is an unacceptably high incomplete or failed abortion rate,
however the efficacy of treatment approaches that of standard
vacuum aspiration when the drug is administered in conjunction with
a low dose of PG. Although further studies are required to assess
the most apropriate dosage regimes, such a combined approach to
menstrual induction should offer an acceptable alternative to
surgery for the interruption of early pregnancy.
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CHAPTER 8
THE RETURN TO OVULATION FOLLOWING MENSTRUAL INDUCTION
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Although the return of cyclical ovarian function following term
delivery has been well studied, the endocrine profile after the
interruption of early pregnancy has been less extensively
investigated.
It has been known for many years that endometrial regeneration and
the return to ovulation is more rapid following abortion than term
delivery. Observing the histological changes in the uterine mucosa
after birth, Williams (1931) remarked that at least 6 or 7 weeks
were required for the disappearance of the placental site in the
normal puerperal woman, but Rutherford and Mezer (1942) noted that
histological evidence of ovulation occurred within 2 or 3 weeks of
early spontaneous abortion.
The return to ovulation after therapeutic termination was also
initially studied using endometrial biopsies. Boyd and Holmstrom
(1972) examined the endometrium from 72 women on the first or
second day of their first menstrual period following induced
abortion, and estimated the day of ovulation by subtracting 14 days
from the date of the period itself. The mean time to ovulation was
22 days, however there was a wide range (10-72 days). 85% of
patients ovulated in the first post-abortion cycle, in contrast to
the findings of Reyniak et al (1975) who, also using endometrial
biopsies, but at different stages of the menstrual cycle, estimated
that only one third of their women ovulated before the first
period.
Recently, the hormonal events following pregnancy termination have
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been investigated in more detail. Lahteenmaki and Luukkainen
(1978) measured plasma estradiol and progesterone concentrations
along with the urinary excretion of luteinising hormone (LH) after
first trimester termination. They suggested that the
refractoriness of ovarian steroidogenesis after abortion was
short-lived, with increasing estradiol concentrations from day 8,
and 83% of their women ovulated prior to the first menses.
Similarly, Blazar et al (1980) assessed the decay of human
chorionic gonadotrophin, estradiol and progesterone, along with the
changing pattern of pituitary gonadotrophin secretion in two groups
of women undergoing vacuum aspiration between 9 and 12 weeks
gestation. One group received preoperative cervical ripening with
15 methyl PGF2 ^ methyl ester, and although not using a strict
randomisation protocol, this group had a more "normal" endocrine
profile, attributed to a possible luteolytic effect of the PG on
the corpus luteum of pregnancy.
The present work has investigated the time to ovulation and the
hormonal characteristics of the first ovarian cycle following
induction of abortion in the first 8 weeks of pregnancy in women
allocated to treatment with either vacuum aspiration or 16,16
dimethyl-trans- A 2-pgei methyl ester pessaries. The return to
ovulation has been studied not only as an indicator of the need for
early contraception, but also to elucidate the effects of abortion
on the synchrony between the ovarian and menstrual cycles.
PATIENTS AND METHODS
32 of the women participating in the comparative study reported in
Chapter 6 volunteered to collect urine samples throughout the first
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post-abortion cycle. 14 had been treated with vacuum aspiration,
whereas the remaining 18 had undergone PG-induced abortion using
gemeprost Img pessaries. All of the women agreed to use barrier
contraception whilst under investigation.
The women were instructed to obtain a sample of first morning urine
passed three times weekly, from the time of the induction of
abortion until the onset of the subsequent menstrual period. The
samples were collected at the routine follow up visits, and were
stored frozen until assayed.
Endocrine asays
The measurement of urinary total estrogen, pregnanediol and hCG was
carried out by Mr H Boyle and colleagues in the Reproductive
Endocrine Laboratories, Centre for Reproductive Biology, University
of Edinburgh. The excretion of total estrogen was measured using a
fluorometric technique, and pregnanediol was estimated using
gas-liquid chromatography, as documented in Chapter 2 (Brown et al,
1968; Chamberlain & Contractor 1968). hCG was assessed using a
specific double antibody radioimmunoassay, using reagents kindly
supplied by Dr Salvatore Raiti, National Hormone and Pituitary
Program, University of Maryland School of Medicine. Details of the
assay have been described by Vaitukaitis et al, 1972.
All hormonal parameters were expressed in relation to urinary
creatinine (total estrogen-pgm/gm: pregnanediol-mg/gm:hCG-IU/gm).
Ovulation and ovarian function
The day of ovulation was estimated using the change in urinary
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pregnanediol excretion in association with changes in total
estrogen excretion and a rise in "hCG" (indicating the IH surge)
when evident. Ovulation was assumed to have occurred the day prior
to that on which the pregnanediol: creatinine ratio first reached
1.0-1.5 mg/gm following the follicular phase. The luteal phase was




The characteristics of the 32 women are shown in Table 8.1. There






















Table 8.1 Patient characteristics. Apart from parity, which is
expressed as the number of women, with the percentage in brackets,
all data are presented as the median and range.
Abortion was successfully induced in all 32 cases, without the need
for subsequent surgical intervention.
Human Chorionic Gonadotrophin
Urinary hCG was measured in 21 women; 9 treated with vacuum
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aspiration, and 12 having received PG pessaries. As there was no
difference between the two treatment groups in terms of the decay
of hCG following abortion, or the return to ovulation (see later),
the results have been combined for analysis.
There was a wide range of pre-treatment hCG values (159-200,000
IU/gm) which was not related to gestational age. Figure 8.1a shows
the decline of hCG following abortion, expressing the data as
percentages of the initial hOG concentration. There was a rapid
fall in the excretion of the gonadotrophin, which reached 10% of
the pre-treatment value after 6 days in each treatment group
(vacuum aspiration-range 2-11 days: PG-range 4-19 days).
It was not possible to obtain an accurate assessment of the half
life(ti) of hCG (the time taken for the concentration of hCG to
decline to half of its previous value), due to the infrequency of
urine sample collection. However, the hOG decay appeared to
consist of an initial rapid component (ti ~ 48 hours), followed
by a slow component as the excretion of the gonadotrophin fell
towards the limit of detection of the assay (figure 8.1b).
Total estrogen
The changes in urinary total estrogen excretion for the 2 groups
combined are presented in figure 8.2a. The initial decline is
plotted in relation to the day of abortion, however the data in the
latter part of the cycle have been corrected relative to the
estimated IH surge (taken as the day prior to the assumed day of






was a gradual increase in the follicular phase, followed by a more
rapid rise prior to, and maintained after, ovulation itself. The
data from 3 women considered not to have ovulated have been
excluded.
Prectnanediol
Figure 8.2b depicts the decline and rise of urinary pregnanediol in
both treatment groups similarly plotted relative to abortion
itself, and the IH surge.
Return to ovulation
29(91%) women showed a luteal phase rise in pregnanediol excretion,
compatible with ovulation. Of the 3 remaining women, 2 had been
treated with PG pessaries. All 3 had experienced regular monthly
periods prior to abortion.
The time to ovulation is shown in table 8.2. There was no
significant difference between the vacuum aspiration and pessary
groups in terms of the return to ovulation, but the subsequent
period was later in that group receiving operative treatment.
VACUUM ASPIRATION PROSTAGLANDIN
(13) (16)
DAYS TO OVULATION 29(16,37) 24(16,32)
DAYS TO MENSES *42(28,49) *36(26,44)
Table 8.2 The return to ovulation after early abortion. Data are
expressed as the median, with the range in parentheses. *p<0.05.
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The median length of the luteal phase was similar in both groups
(vacuum aspiration - 13 days (range 10-15): PG - 11 days (range
7-14)). However 13(45%) women, 4(30%) in the surgical group and
9(56%) in the PG group, exhibited a luteal phase of <11 days. The
difference between the 2 groups was again not statistically
significant.
Although the return to ovulation was not directly related to the
half life of hCG, there was a correlation between the day on which
the urinary pregnanediol: creatinine ratio first fell to less than
1.5 mg/gm, and the day of the return of ovulation (Figure 8.3).
DISCUSSION
The findings of the present study are in accord with previously
cited data assessing the endocrine profile of the first
post-abortion cycle.
Lahteenmaki and Inukkainen (1978) monitored ovarian function by
measuring plasma estradiol and progesterone concentrations in 18
women after first trimester vacuum aspiration. They noted an
ovulation rate of 83%, however the luteal progesterone
concentration was low compared with previously documented normal
cycles. In addition, assessment of the plasma concentrations of
hCG/IH and FSH, 3 times weekly, in the same group of subjects
(Lahteenmaki, 1978), revealed that although pituitary function
recovered within 4-9 days of abortion, the decay of hCG was slow,
with complete disappearance occurring after 37.7 days. Blazar et
al (1980) similarly investigated the hormonal patterns following
early abortion in 15 women undergoing first trimester vacuum
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ripening using 15 methyl PGE2 methyl ester pessaries. 13(87%)
individuals showed a pre-ovulatory LH peak (7(100%) in the FG
group), occurring between day 16 and 35, but as with Lahteenmaki's
findings, the subsequent luteal phase progesterone concentrations
were low, reaching > 5 ng/ml for 5 days in only 6(40%) individuals,
all of whom received pre-operative prostaglandin. The occurrence
of more "normal" cycles in the PG-treated group was attributed to
either a luteolytic effect, or a specific ovarian action leading to
improved follicular development. In the absence of direct evidence
for a luteolytic role for the prostaglandins in the human (Baird,
1985), the former hypothesis would seem less likely, and although
there was a significant difference between the peak follicular
estradiol concentrations in the 2 groups (vacuum aspiration alone -
228 pg/ml: PG-301 pg/ml; p<0.05), there was no difference between
the groups in relation to the initial decay of estradiol at the
time when the PG was administered. However the progesterone
concentration declined more rapidly in the PG-treated group (the
nadir occurring after 5.6 days as opposed to 7.6 days; p<0.01), and
it may be that the more "normal" follicular activity is related to
the acceleration in the rate of decay of progesterone
concentrations.
Although the changes in urinary steroids and hCG in the present
work are similar to these previous studies, the use of urine rather
than plasma results in differences in the interpretation of
multi-component hormonal decay curves. For example, the initial
rapid component decay of hOG in Lahteenmaki' s work (ti ~ 15hrs)
represents disappearance of the gonadotrophin from plasma. Though
an accurate estimate of hCG 11 was not obtained here, the
development of subsequent ovarian function and ovulation occurred
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in the presence of detectable hCG, as previously reported
(Lahteenmaki, 1978; Blazar et al, 1980).
An ovulation rate of 91% compares well with previous studies using
both histological and endocrine methods, but although the luteal
phase was short in 13(45%) women, the relatively infrequent urine
sampling has prevented more specific comment regarding luteal
function. Regardless of this, the high ovulation rate in the first
cycle post-abortion demands the use of reliable contraception from
an early stage.
The return to ovulation on day 24 and day 29 in the PG and vacuum
aspiration groups respectively, also agrees with previous findings,
however, there was a wide range (16-37 days). This delay to
ovulation was not related to the decline (ti) of hCG, but
correlated with the day on which the urinary
pregnanediol: creatinine ratio first fell below 1.5 mg/gm. As this
would represent progesterone from both the corpus luteum and the
products of conception, and the hCG would mirror remaining
trophoblastic activity, it is likely that delay in the decline of
pregnanediol: creatinine is related to a delay in luteolysis. Once
the corpus luteum's progesterone-secreting activity has been
overcome, the return of pituitary gonadotrophin release, even in
the presence of some hOG, would result in the resumption of
cyclical ovarian activity. Assuming a normal follicular phase, the
delay in the occurrence of ovulation, as the data suggest, would be
directly related to delay in the initiation of follicular activity.
Delay in luteolysis may result from continued support by hOG. This
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residual hCG activity will derive from both its long half-life, and
any remaining trophoblast. The present data do not allow the
relative contributions of these two factors to be separated,
however there was no difference between the two treatment groups.
In addition, the part played by the hCG half-life will depend on
the initial concentration of hCG - which will result in varying
absolute concentrations of hCG after any unit of time - and the
sensitivity of the individual corpus luteum to the gonadotrophin
itself.
In conclusion, most women ovulated in the first post-abortion cycle
and there was no difference between the 2 treatment groups.
However, the return to ovulation occurred over a wide range, and
this was related to the decline of pregnancy corpus luteum
function. What then is the clinical significance of this delay to
ovulation?
The need for early reliable contraception has already been
mentioned, but if menstrual induction is to be considered as a
routine method of fertility control, it is necessary to discuss the
effect of the delay to ovulation on the synchrony between the
ovarian and menstrual cycles.
The problem of repeated menstrual induction is outlined in figure
8.4. In A, ovulation (OV) occurs 14 days after induction of menses
with a "menstrual inducer" (M) in month 2, and M is taken for the
second time at the appropriate stage. In B, the menstrual inducer
is merely taken earlier in the secretory phase. If, however,
ovulation is delayed by 2 weeks after induction of abortion in
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cycle 1, and this occurred in 11(38%) women in the present study
(see C), the menstrual inducer is taken progressively earlier in
the cycle, and by cycle 3 it is taken in the follicular phase. No
bleeding will ensue and the subject will assume that she is still
pregnant. This disruption of the synchrony between the ovarian and
menstrual cycles represents a major constraint to the use of early
pregnancy interruption as a long term method of fertility control,
however, further studies are required to assess whether these
problems could be overcame by administering therapy in very early
pregnancy.
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PROSTAGLANDINS AND MENSTRUAL INDUCTION: CONCLUSION
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The clinical potential of the prostaglandins as agents for
menstrual induction offers a practical alternative to vacuum
aspiration. The effectiveness of one such agent has been described
both alone (Chapter 6) and in combination with RU486 (Chapter 7),
however, the widespread application of medical abortion remains
limited.
Firstly, the abortion process is not immediate, as opposed to
complete vacuum aspiration, and takes place over some days. Many
women prefer the more expeditious surgical option, usually
performed on an out-patient basis. Secondly, in the absence of a
treatment method with a reliability approaching 100%, a high degree
of patient compliance is required, particularly in relation to
follow up. At operation the uterine contents can be examined to
confirm expulsion of the fetus. This is not practically possible
using medical agents for early termination, and makes follow up
mandatory to audit treatment success. In addition, the inability
to confirm the removal of fetal and trophoblastic tissue from the
uterine cavity prevents the exclusion of ectopic gestation. The
delayed diagnosis of ectopic pregnancy in a woman undergoing
menstrual induction using RU486 has been reported (Kovacs et al,
1984), and in the present work one patient referred for the
comparative study in Chapter 6 had an ovarian ectopic gestation.
She had conceived with an intra-uterine contraceptive device in
situ, and her only presenting complaint had been menstrual spotting
for a week, which had excluded her from the study itself. Although
the diagnosis of intra-uterine pregnancy can be made by ultrasound,
this is less reliable in very early pregnancy, in the absence of a
definite fetal pole or fetal heart. The possibility of ectopic
pregnancy should always be considered, especially in those
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situations where associated predisposing factors for ectopic
implantation exist.
The other major drawbacks to the acceptability of medical agents
for menstrual induction are the occurrence of side effects, and the
disturbed synchrony between the ovarian and menstrual cycles
(Chapter 8). The attempted improvement in gastro-intestinal side
effects by the administration of a low dose of PG in a controlled
release fashion was unsuccessful (Chapter 6), however this approach
should be further investigated using different PG analogues.
Slow-release drug administration could also be applied in other
situations, such as the induction of second trimester abortion
(Bygdeman et al, 1984), the management of intrauterine death, and
the induction of labour (Greer et al, 1986).
A combination of a low dose of PG with RU486 achieved an acceptable
abortion rate with a partial improvement in gastro-intestinal
effects (Chapter 7), though nausea and vomiting continued to
occur. It may be that the incidence of these side effects will not
be improved in early pregnancy without resorting to specific
antiemetic premedication.
The delay to ovulation in some women following menstrual induction
with PG or vacuum aspiration could result in asynchrony between the
ovarian and menstrual cycles if treatment were prescribed on a
regular basis (Chapter 8). This problem might be overcome by
administering the menstrual inducer in very early pregnancy, or by
using combination drug therapy, however, a delay to ovulation of 32
days has been noted using luteal phase menstrual induction with
RU486 in rhesus monkeys (Hodgen, 1985).
13 1.
In view of the increasing interest in medical agents for menstrual
induction (Rosen et al, 1979), much further research is required in
this field of fertility control.
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APPENDIX 1: ABBREVIATIONS
The following abbreviations have been employed.
FSH Follicle stimulating hormone
hCG Human chorionic gonadotrophin
IPT Immunological pregnancy test
LH Luteinising hormone
MBL Menstrual blood loss
MOX methyl oxime
PG Prostaglandin




APPENDIX 2: STATISTICAL METHODS
Non parametric tests have been employed (Siegel, 1956). The
differences between paired and independent samples have been
assessed using the Wilcoxon signed rank and Wilcoxon rank sum tests
respectively. Analysis of frequency tables has been performed
using the 2 test and the Fisher exact probability test, and
bivariate data have been analysed using Spearman's rank
correlation.
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ABSTRACT
The interaction between the prostaglandin production of the human
endometrium and myometrium has been further investigated using intact
pieces of endometrium in homogenates of myometrium. There was an
increase in the production of 6 oxo PGF,^ when these tissues were
incubated together, whereas there was no change in the production of
PGE, PGF2< or 13, 14 dihydro 15 - keto PGF2<. This endometrial -
myometrial interaction could have important implications in the
pathogenesis of menorrhagia.
INTRODUCTION
A role for the prostaglandins (PG) in local uterine
pathophysiology has been suggested for some time, and since the
discovery of an acidic lipid in the menstruum with oxytocic properties
(1), later found to be PGE2 and PGF2f<( (2), these substances have been
implicated in the aetiology of various disorders of menstruation.
An increase in the concentration of both PGF2c< and PGE2 has been
measured in the menstrual fluid of patients with dysmenorrhoea (3),
whereas excessive menstrual bleeding appears to be associated with an
imbalance in uterine PG production (4,5). Endometrium from women with
ovulatory dysfunctional uterine bleeding synthesises more PGE2 than
that of normal women, and in individuals with anovulatory
dysfunctional bleeding, excessive menstrual loss is associated with a
relative deficiency in PGF2^< synthesis (6). There is an inverse
relationship between the ratio of PGF2*( :PGE2 and the amount of blood
lost, and it may be therefore that menstrual loss is determined by the
relative synthesis of prostaglandins with mainly vasoconstrictor
properties on the one hand (PGF2^) as opposed to those with
vasodilatory properties (PGI2,PGE2) on the other (7).
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Within the uterus the major prostaglandin output is derived from
the endometrium,- with the prostaglandins E2 and F2»<, predomi nati ng,
although small amounts of prostacyclin, measured as 6 oxo PGF, <, are
found (8). This contrasts with the situation in the myometrium, where
6 oxo PGF, K, is the major product of arachidonic acid metabolism in
both animals (9) and man (10). An interaction between the PGs from
the two uterine tissues has been suggested by Smith et al (11), who
demonstrated that the endometrium from women with menorrhagia could
enhance the myometrial production of prostacyclin, and more recently
these observations have been confirmed (8). Each of these studies has
emplo^d broken cell preparations, both with and without incubationwith C - labelled arachidonic acid respectively.
The present work has further investigated the interaction between
homologous endometrium and myometrium, using intact pieces of
endometrium. In addition to assessing the change in the synthesis of
PGE2,PGF2 < and 6 oxo PGF( ^ , the effect of this combined tissue
incubation on the major metabolite of PGF2^, 13, 14 dihydro 15 - keto
PGF2c< (PGFM2 ), has also been observed.
METHODS
Tissue Collection and Prostaglandin Measurement
6 women suffering from benign uterine disease, each with a
subjective complaint of menorrhagia, were admitted for abdominal
hysterectomy in the luteal phase of the cycle. At operation, samples
of both endometrium and myometrium were placed in ice - cold modified
199 medium (Flow Laboratories, U.K.), and transported to the
laboratory. After blotting and weighing both types of tissue, a
myometrial homogenate was prepared in 199 medium (using a Polytron
homogeniser), at a final concentration of 10 mg/ml. Thereafter, small
pieces of endometrium (5.2+^ 0.3 mg(mean +_ S.E.M) n = 48) were placed
in either 1 ml of 199 medium or 1 ml of the myometrial homogenate, and
these samples were incubated at 37°C in a water bath for 1 hour , with
gentle shaking. 1 ml samples of the myometrial homogenate alone, and
control samples of 199 medium were also processed in similar fashion.
Following the incubation, the pieces of endometrium were removed, and
the media were stored at -20°C until assayed.
Prostaglandin concentrations were measured using standard
radioimmunoassay techniques (12). Antibodies raised against PGE2 and
PGF2y^ (Dr J. Hennam, Kings College, London), 6 oxo PGF, < (Dr J. A.
Salmon, Wellcome Research Laboratories, Beckenham), and PGFM2 (Upjohn
Ltd), were employed - and as the antibody against PGE2 cross-reacted
significantly with PGE, , the value for the concentration of PGE
presented includes prostaglandin from both the 1 and 2 series. Inter
and intra assay coefficients of variation, taken over 10 sequential
assays and in duplicate 10 times within the same assay, were 12.2% and
14.4% for PGF2*s, 10.1% and 11.2% for PGE, 11.1% and 14.5% for 6 oxo
PGFvk, and 11.0% and 13.7% for PGFM,.
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Endometrial Dating
In all experiments, a portion of endometrium was placed in formol
saline for histological dating (13). The occurrence of ovulation was
indicated by the presence of secretory endometrium, along with a serum
progesterone concentration greater than 9 nmol/L.
Statistical Analysis
Non parametric tests were used (14), the significance between
paired samples being assessed by the Wilcoxon signed - rank test.
RESULTS
The character!'sties of the 6 patients are seen in Table 1. All
were in the secretory phase of the cycle, and all showed histological
evidence of luteal function. Each of the women complained of heavy
periods, with associated dysmenorrhoea in two cases, however their
menstrual loss was not assessed objectively.
AGE (yrs) PARITY CYCLE DAY
1 46 3+0 4/28 22
2 43 1+0 8/25 26
3 46 4+2 8/26 25
4 35 4+1 11/24 24
5 40 2+0 7/23 22
6 40 4+0 6/21 17
Table 1 Patient characteristics.
Endometrial prostaglandin production, both alone and in
combination with myometrium, is presented in Figure 1. After
correcting for the production of prostaglandin by the myometrial
homogenate alone, the value for the combined incubate is expressed in
pg/mg endometrium per hour. As can be seen, there was an increase in
the production of 6 oxo PGF,< by the endometrium when incubated with
myometrium, however, there was no significant change in the production
of either PGE, PGF2<, or the metabolite PGFM2.
DISCUSSION
It has previously been shown that endometrial homogenates from
women with menorrhagia have a greater capacity than normal endometrium
to generate 6 oxo PGF,*/ when incubated in combination with control
homogenates of myometrium (11). This increased 6 oxo PGf^production
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was foundry incubating the tissues with exogenous precursor in the
form of C labelled arachidonic acid. Dimov et al, (15) have
recently questioned the validity of such incubation techniques,
suggesting that only qualitative conclusions should be drawn.
However, Kelly et al (8), again working with both endometrial and
myometrial homogenates, and with the endometrium itself acting as the
source of endoperoxide precursor, have confirmed the increase in 6 oxo
PGF,>c seen on combined incubation. Furthermore, this group has shown
that the variation in 6 oxo PGF(< production is a characteristic of
the endometrium itself, rather than the myometrium.
The present work further supports the hypothesis that when these
two uterine tisssues are combined, the intact endometrium can supply
precursor endoperoxide to the myometrium, where it is converted
primarily to prostacyclin and thence to 6 oxo PGF.cX^. That it has not
been necessary to prepare an endometrial homogenate to demonstrate
this increase in 6 oxo PGf^ production would suggest that the intact
endometrium could release precursor endoperoxide in vitro. There was
no change in the production of PGE, PGF2 < or PGFM2 on combined
incubation, in agreement with previous observations (11), although
Abel and Kelly (10) have suggested that a decrease in the production
of PGE and PGF2<may result from the diversion of endoperoxide towards
prostacyclin synthesis.
The variable degree by which the 6 oxo PGF,K concentration
increased in the present experiments (by a factor of 1.3 to 6.7
times), might have been related to the level of menstrual blood loss.
However, further studies recruiting women with objectively assessed
periods would be necessary to test this, for it is evident that almost
50% of women presenting with a subjective complaint of menorrhagia
will have a measured monthly blood loss within normal limits (16).
In conclusion, the presented work illustrates that an interaction
between endometrial and myometrial prostaglandin production is
possible, and that endoperoxide precursor can be released from intact
endometrium. Although such in vitro data do not necessarily prove
that this mechanism exists in vivo, it is interesting to consider its
possible consequences. Kelly et al, (8) have recently suggested that
there might be an increased availability of arachidonic acid in the
endometrium of women suffering from menorrhagia. In the event of the
resultant increase in precursor endoperoxide availability, not only
might the synthetic pathway towards PGF2< become saturated, leading to
a diversion of endoperoxide towards PGE2 non-enzymatically (and thus
causing an increase in the PGE2:PGF2cx ratio), but also more PG12 could
be formed, both in the endometrium, and, in addition, in the large
muscle mass of the myometrium. This increase in prostacyclin
production could have important implications in the pathogenesis of
menorrhagia.
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Figure 1 Combined endometrial - myometrial incubations: prostaglandin
production in pg/mg/hr (mean + standard error of the mean -
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CONTRACEPTION
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ABSTRACT
The termination of early pregnancy (<56 days amenorrhoea) has been
investigated using 16,16—dimethyl-trans-tx 2-PGE ( methyl ester in a
controlled release preparation. The onset of crampy abdominal pain was
seen after 270 + 39 minutes and bleeding occurred after 603 + 95 minutes.
Two (15%) patients required no pain relief during treatment, however 5
(38%) requested oral analgesia, and in 6 (46%) individuals the pain was
severe enough to warrant parenteral opiates. The overall success rate for
complete abortion was 85%. No serious adverse effects were seen, but
vomiting occurred in 2 (15%) women, and diarrhoea in 3 (23%). Although the
use of this prostaglandin analogue in slow release form provides an
effective treatment method for early abortion using a reduced total dose of
prostaglandin, the acceptability of the drug as an agent for menstrual
induction continues to be limited by the occurrence of troublesome
gastro-intestinal side effects.
INTRODUCTION
Since the introduction of the 1967 Abortion Act, the annual number of
therapeutic abortions has increased steadily, and in 1982 a total of
163,045 pregnancies were terminated in England and Wales (1). In Scotland,
after an initial upward trend, the annual number of such abortions
performed has reached a plateau, and in 1983,8,419 cases were reported, 89%
of which were at a gestation of 13 weeks or less.
Vacuum aspiration of the uterine cavity under general anaesthesia continues
to be the most widely accepted method for pregnancy termination in the
first trimester. However, such procedures are not without risk, and the
recognition that the complication rate associated with therapeutic abortion
is related to both the gestational age and the anaesthetic and surgical
techniques employed, has led to the development of a medical approach to
early abortion.
Initially the naturally occurring prostaglandins (PG) of the E and F series
were used (2), and subsequently a number of analogues have been
synthesised, with increased stability and more specific uterine activity
(3,4,5), but gastro-intestinal associated side effects have continued to be
a major problem, occurring in up to 40% of cases (6).
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Although a lower dose of prostaglandin can be used to decrease the
incidence and severity of these side effects, this may lead to a reduced
success rate for abortion itself. An alternative solution would be to
administer the prostaglandin in a controlled release form, thereby
lessening the "bolus effect" each time an individual dose of drug is
given.
The present work has investigated the use of 16,16-dimethyl-trans-A2-PGE,
methyl ester incorporated into such a controlled release device, for the
interception of early pregnancy (<56 days amenorrhoea).
PATIENTS AND METHODS
Thirteen women with pregnancies of less than 56 days gestation were
recruited for study. Gestational age was assessed by menstrual history
and clinical examination, with the addition of pelvic ultrasound where
necessary. In all cases, pregnancy was confirmed with an immunological
pregnancy test (7). Patients with evidence of abnormal pregnancy or
spontaneous abortion were excluded from study, as were women with medical
complications such as cardiovascular or pulmonary disease, allergy, or
epilepsy. Pregnancy termination was indicated under the 1967 Abortion
Act: local ethical committee approval was granted for the project, and
written informed consent was obtained from each woman prior to proceeding
with treatment.
On admission to hospital, a device containing 3 mg of 16,16-
dimethyl-trans-A 2-PGEi methyl ester incorporated into a strip of
polyethylene-oxide based hydrogel (measuring 1.3 x 10 x 30 mm) was placed
in the posterior fornix of the vagina. After 1 hour, the women were
allowed to get up, and they remained in hospital for 24 hours.
Prophylactic medications were not prescribed, however analgesics
(paracetamol, 1 gm; dihydrocodeine, 30 mg; or pethidine 100 mg),
antiemetics (cyclizine, 50 mg) or other preparations, such as
antidiarrhoeal agents, were administered on request. No dietary
restriction was enforced during treatment.
The devices were removed prior to discharge from hospital. Patients were
given appropriate contraceptive advice, and arrangements were made for
follow-up at 1 week, 2 weeks, 4 weeks and fortnightly thereafter, until
the onset of the next period. The abortion was considered successful at
the 2—week visit if there was minimal vaginal bleeding, the cervix was
closed, the uterus was normal in size, and the pregnancy test indicated
that the concentration of human chorionic gonadotroph]'n was falling.
RESULTS
The 13 women, whose average age was 26.0 + 1.9 years (mean + SEM), were
at a mean gestation of 51.1 + 1.2 days. Four (31%) individuals were
parous, and one had undergone previous pregnancy termination in the
second trimester.
Crampy abdominal pain was seen after 270 + 39 minutes, and the onset of
bleeding occurred after 603 + 95 minutes. The degree of blood loss was
not assessed objectively, but in no case was the subjective loss so great
as to warrant either blood transfusion or emergency uterine evacuation.
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Only 2 patients required no pain relief during treatment. Five requested
oral analgesia, and 6 considered the pain severe enough to require
parenteral opiates. Two women suffered from vomiting, and diarrhoea
occurred in 3.
The successful induction of bleeding followed by abortion occurred in 11
(85%) women without the need for surgical intervention. The mean
duration of bleeding in these individuals was 10.9 + 1.7 days, and in 8
(73%) cases, mild period-like pain was experienced during the first week
of follow-up.
The remaining two women underwent uterine evacuation under general
anaesthesia. One patient was admitted on the fourth day post-treatment
with abdominal pain and vaginal discharge; a clinical diagnosis of
retained products of conception was made, and she proceeded to surgical
evacuation under antibiotic cover. The second woman underwent uterine
evacuation and diagnostic laparoscopy on the 24th day following treatment
because of continuing vaginal bleeding, tenderness in the right fornix,
and a persisting positive pregnancy test. Operation revealed a luteal
cyst on the right ovary, and curettage confirmed the presence of
chorionic villi in the uterus.
The amount of drug administered to each patient was measured by assaying
the residual compound in the device, using high pressure liquid
chromatography. The median dose received was 1.65 mg (range 1.16-1.86
mg), representing a percentage release of 53% (range 39%-62%). There was
no relationship between the success rate or the incidence of side
effects, and the dose of drug administered.
DISCUSSION
Although menstrual induction has been performed using a variety of
synthetic prostaglandin analogues, with success rates of up to 90-95%,
side effects, particularly associated with the gastro-intestinal tract,
have limited the acceptability of these drugs as therapeutic agents. The
incidence of vomiting and diarrhoea may be reduced by routine
premedication with antiemetic or anti-diarrhoeal agents (8,9).
Alternatively, the use of a lower dose of the prostaglandin itself would
improve these dose-related side effects, but this may lead to a reduced
success rate for abortion itself. However, the administration of the
prostaglandin in a local controlled release form will lessen the "bolus
effect" each time an individual dose of drug is given, and may maintain
an acceptable success rate with a reduced total drug dosage.
The present work has assessed the use of a device releasing 16,16-
dimethyl-trans-A2 -PGE1 methyl ester in controlled release fashion. This
prostaglandin analogue has been widely employed to induce therapeutic
abortion in both the first and second trimesters of pregnancy in the form
of 1 mg vaginal pessaries (10,11,12) and more recently it has been
synthesised in a slow release device made of a 3-layered water soluble
polymer (13). In the latter study, abortion was achieved in 21 (84%)
late second trimester pregnancies within 18 hours of treatment with
devices containing 1.5-2.0 mg of drug, but vomiting and diarrhoea were
seen in 9 (35%) and 3 (12%) cases,respectively.
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Here the drug has been incorporated into a strip of polyethylene
oxide-based hydrogel in which cross-linking is induced by the use of an
aliphatic difunctional isocyanate and an aliphatic triol. On exposure to
body fluids, the polymer swells to about three times its dry volume, at a
rate which can be predetermined by the composition of the matrix. The
drug then diffuses out of the matrix at a zero order rate, over a time
period dependent upon the thickness of the device, the degree of
crystal 1inity of the polymer, and the actual prostaglandin used. All the
drug is not released within 24 hours, however measurement of the residual
prostaglandin in the devices themselves indicated a reproducible release
pattern.
The success rate of 85% compares well with that of other studies using
this prostaglandin in pessary form, however the incidence of vomiting and
diarrhoea is not significantly different from that previously cited by
Smith and Baird (11) in 1980 (p>0.05). Additionally, in a further 30 women
treated with 16,16 dimethyl-trans-A2-PGEA methyl ester in pessary form,
the incidence of vomiting (23%) and diarrhoea (33%) was similar to that
seen using the slow release device (Cameron & Baird, unpublished data).
Although safe and effective,^ the failure rate of 5-15%, resulting in the
need for stringent follow—up arrangements, does limit the use of such
medical agents for menstrual induction. In addition, at vacuum
aspiration it is possible to inspect the products of conception to
confirm the presence of an intra-uterine gestation. This assumes more
importance especially in cases of very early abortion with minimal
uterine enlargement, and in situations where associated predisposing
factors for ectopic implantation exist.
In conclusion, the use of 16,16-dimethyl-trans-A2-PGE-, methyl ester in
this slow release form provides an effective, safe treatment method for
early abortion. However, although a reduced dose of prostaglandin is
employed, there is no consistent improvement in the incidence of
gastro-intestinal associated side effects, compared with other studies
using the same prostaglandin in pessary form.
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Abstract
Abortion was attempted in 39 women in early pregnancy
(<56 days amenorrhea) with the progesterone antagonist RU486
alone (150 mg per day for 4 days) or in combination with a
PG analogue, 16,16-dimethyl-trans-A2-PGE-j_ (Gemeprost) in the
form of a 1 mg vaginal pessary. Complete abortion was also
attempted in 5 women who received RU486 together with 2x1
mg PG pessaries. Vaginal bleeding followed by complete
abortion occurred in 18 of 19 women who received RU486 + l
mg PG pessary as compared to only 12 of 2 0 women who
received RU486 alone (P<0.01). All women who received RU486
+ 2 mg Gemeprost had a complete abortion. The onset of
crampy abdominal pain (median: 3 vs 4 days) and vaginal
bleeding (3 vs 3 days) was similar in the RU486 and RU486 +
PG groups, respectively. Slightly less than half the
patients in both groups had nausea and/or vomiting, but the
incidence did not differ from that occurring prior to
treatment. The mean duration (range) of vaginal bleeding
[RU486 alone: .10 (0,29) days and RU486 + PG: (5,34)
days],and the measured blood loss [RU486: 53 (2,227) ml and
RU486 + PG: 81 (32, 222) ml] did not differ significantly
between the two treatments. It is concluded that the
combination of RU486 and a single PG vaginal pessary is a
highly effective means of inducing therapeutic abortion in
early pregnancy and offers an alternative to surgery.
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Introduction
Therapeutic abortion can be performed effectively and
safely by vacuum aspiration of the uterus under local or
general anaesthesia up to 12 weeks amenorrhoea (1).
However, because complications are related to gestational
age and anaesthesia, attempts have been made to develop
medical means of terminating pregnancy in the first 8 weeks
avoiding the necessity of surgery. Oxytocic agents such as
prostaglandins E and F applied locally into the uterus will
induce abortion in the first trimester (2,3). A variety of
more stable and uterine-specific analogues has been
developed which induces abortion in over 90% of women when
given by vaginal pessary or intramuscular injection (4-7).
However, their widespread acceptance is limited by a
relatively high incidence of gastrointestinal side effects.
The myometrium is maintained in a quiescent state
throughout pregnancy due to the high levels of progesterone
(8) . Although antagonism of the biological effect of
progesterone by the progesterone receptor antagonist RU486*
results in an increase in myometrial activity and uterine
bleeding, the incidence of incomplete abortion (about 30%)
is unacceptably high (9,10). Recently it has been reported
that a higher rate of complete abortion can be achieved in
early pregnancy if RU486 is combined with a sub-therapeutic
dose of sulprostone - a potent analogue of prostaglandin E2
(11). In the present study we compare the results of the
administration of RU486 alone or in combination with a
single vaginal prostaglandin pessary (Gemeprost: 16,16-
dimethyl-trans-A 2-prostaglandin E1)** in women in early
pregnancy (<56 days amenorrhoea) . In this way it was hoped
that a highly effective medical means of inducing abortion
could be developed with minimal side effects.
Patients and Methods
Forty-five women with pregnancies of less than 56 days
amenorrhoea were recruited for the study. Gestational age
was assessed by menstrual history and clinical examination,
supported by pelvic ultrasound. In all cases, pregnancy was
confirmed with an immunological pregnancy test (12).
Patients with evidence of multiple pregnancy or
spontaneous abortion were excluded from the study, as were
women with medical complications such as cardiovascular or
pulmonary disease, allergy or epilepsy. Pregnancy
* 17 B-hydroxy-11 B - (4-dimethylaminophenyl)-17 a - (1-propynl) -
estra-4,9-dien-3-one; Roussel Laboratories, Ltd., Broadwater
Park, North Orbital Road, Uxbridge, Middlesex, U.K. UB9 5HP.
** Cervagem; May & Baker, Ltd., Dagenham, Essex, U.K. RM10
7XS.
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termination was indicated under the 1967 Abortion Act; local
ethical committee approval was granted for the project, and
written informed consent was obtained from each woman prior
to proceeding with treatment.
Patients were randomly allocated to the study groups.
Twenty women rceived RU486 alone, given orally at a dose of
150 mg daily for 4 days. The remainder were also treated
with the same dose of RU486 for 4 days, but in addition they
received 16,16-dimethyl-trans- A 2_PGE1 methyl ester in the
form of vaginal pessaries (Gemeprost) 48 hours after
commencing the antigestogen. In this group, the first 5
women were treated with 2 x 1 mg of PG, therefore the PG
dose was reduced to 1 mg in total.
Prophylactic medication was not prescribed; however,
analgesics (paracetamol 1 gm; dihydrocodeine 30 mg;
pethidine 100 mg or diamorphine 5 mg) , antiemetics
(cyclizine 50 mg) or other preparations, such as anti-
diarrhoeal agents, were administered as required. No
dietary restriction was enforced.
After treatment, arrangements were made for follow-up
at 1 week, 2 weeks, 4 weeks and then every 2 weeks until the
onset of the next period. Abortion was considered
successful at the 2-week visit if there was minimal vaginal
bleeding, the cervix was closed, the uterus was normal in
size and the serum concentration of human chorionic
gonadotrophin had fallen. In the event of treatment
failure, the uterus was evacuated under general anaesthesia.
In 24 women (11 on RU486 alone and 13 on RU486 + PG) ,
blood loss was measured using a modification of the alkaline
haematin method (13). Soiled pads and tampons were placed
in molar sodium hydroxide and thoroughly mixed. Twenty-four
hours later, an aliquot was taken and, after filtration, its
optical density was measured at 450 nm. Blood loss was then
calculated by comparing this with the optical density of a
peripheral blood sample similarly processed.
Statistical Analysis
The Wilcoxon rank sum test and the Fisher exact
probability test have been used.
Results
All five women receiving the higher dose of PG aborted
completely but had crampy abdominal pain. Accordingly, in
the remaining women the dose of PG was reduced to 1 mg and
the presented data, therefore, refer to those patients who
received either RU486 alone (n=20) or RU486 + PG (n=20). In
the latter group one woman, in whom treatment was
discontinued after 36 hours because of side effects prior to
\ t r\ \ / r: x * r> r~r> ir>ot \rr^i o a \t/"\ c a c 1
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receiving any PG, has been excluded from analysis. There
were no significant differences between the characteristics
of the 2 groups (Table).
Table: Patient Characteristics
RU486 (20) RU4 8 6 + PG (19)
AGE (years) 25 (17,41) 23 (17,38)
HEIGHT (cm) 168 (142,175) 165 (157,173)
WEIGHT (kg) 64 (47,88) 61 (51,68)
FAROUS (%) 5 (20%) 2 (11%)
GESTATION (days) 47 (39,56) 47 (35,56)
Apart from parity, which represents the number of
parous women with the percentage in brackets, the
data presented show the median and range.
Bleeding followed by complete abortion occurred in only
12 (60%) women in the RU486 group but in 18 (95%) of those
women treated in combination with PG (p<0.01). At uterine
evacuation there was evidence of fetal tissue in all 8
treatment failures in the former group, and in 5 cases the
fetal heart was present on ultrasound scanning prior to
surgery. The one "failure" in the RU486 + PG group
underwent curettage 6 weeks after initial treatment because
of persistent mild discharge and an ultrasound appearance
consistent with the appearance of minimal debris within the
uterus. Necrotic trophoblastic tissue was demonstrated
histologically.
There were no differences between the two groups in
terms of the onset of crampy abdominal pain or vaginal
bleeding. The median (range) day of onset was 2 (0,4) and 3
(0,4) for pain, and 3 (1,6) and 3 (1,4) for bleeding in the
RU486 alone and RU486 + PG groups, respectively. In
addition, there was no statistically significant difference
in the use of analgesics between the treatment groups, with
5 (25%) women in the RU486 group and 9 (47%) in the RU486 +
PG group requesting pain relief (N.S.; P=0.09). Only 3
(16%) women, all of whom were in the PG-treated group,
required pethidine or diamorphine (N.S.; P=0.1). No serious
complications were seen. Eleven (55%) women in the RU486
group and 7 (37%) in the RU486 + PG group complained of
nausea during the first 2 days of treatment, whereas in 2
(11%) cases in the latter group this was only noticed after
the PG administration. It should be noted, however, that
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the incidence of nausea in the 2 groups on the day prior to
treatment with RU486 was 58% and 69%, respectively, in the
13 women whose data were available for analysis.
It was possible to record the incidence of vomiting and
diarrhoea in the 48-hr period prior to treatment in 13 and 9
women in the RU486 and RU486 + PG groups. Vomiting occurred
in 1 of 13 women prior to treatment with RU486 alone and in
3 (33%) of 9 before they received the combined therapy.
Duing therapy the number of women with vomiting was 3 (15%)
and 6 (32%) in the RU486 alone and RU486 + PG groups,
respectively. There was no significant difference between
the 2 groups, nor was there any difference before and after
treatment in either group, or in the incidence of vomiting
before and after the administration of PG in the combined
treatment group. Diarrhoea occurred on day 2 in 1 woman in
the RU486 alone group, and in 1 woman on day 3 in the RU486
+ PG group.
Data were available on blood loss following treatment
in 24 women who collected their soiled sanitary protection.
The median (range) loss was 53 (2,227) ml (n=ll) for the
RU486 alone group and 81 (32,222) ml (n=13) for the combined
RU486 + PG group (N.S.; P>0.05). Five of the 11 patients in
the RU486 alone group had undergone uterine evacuation for
failure to induce abortion; the median blood loss of the
remaining 6 women was 62 (45,227) ml.
One patient in the RU486 alone group had uterine
evacuation performed as an emergency because of heavy
bleeding 3 days after the cessation of treatment. Although
the degree of blood loss was not measured objectively, she
was not clinically in shock and it was not considered
necessary to give her a blood transfusion. The patient's
haemoglobin concentrations before treatment and the day
after operation were 12.2 and 11.4 g/dl. Blood transfusion
(2 units) was required for another woman treated with RU486
alone who bled heavily following uterine evacuation for
treatment failure. No such cases occurred in the RU486 + PG
group.
Excluding those women who required operative
intervention, bleeding persisted for 10 (0,29) days in the
RU486 alone group and 11 (5,34) days in the PG-treated
women.
Finally, the interval to the subsequent menstrual
period was 39 (23,64) days and 35 (18,48) days in the RU486
and RU486 + PG groups, respectively.
Discussion
While the prostaglandins have been the only compounds
investigated on a large scale for the medical interruption
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of early pregnancy, the development of the antiprogesterone
agents has offered an alternative approach (14). Initial
studies have demonstrated that, although the progesterone
receptor antagonist RU486 is an effective abortifacient, the
incidence of incomplete or unsuccessful abortion when the
drug is administered alone is unacceptably high (9,10).
The present study has compared the use of RU486 alone
and in combination with 16,16-dimethyl-trans-Z^-PGE-^ methyl
ester, a PG which has been widely used in pessary form to
terminate pregnancy in both the first and second trimesters
(15-18). Such a combined approach has been advocated on
theoretical grounds in that, although the antigestogen may
be highly effective at intercepting the pregnancy itself, it
may not induce adequate uterine activity to expel the
products of conception (19). Furthermore, the fact that
antigestogens sensitise the uterus to oxytocic agents (11)
should lead to a reduction in the dose of PG required to
induce abortion, with a consequent fall in the incidence of
unwanted side effects. Using various dose regimens of RU486
in combination with a single low dose of 16-phenoxy-
tetranor-PGE2 methyl sulfonylamide, a complete abortion rate
of nearly 100% has been reported (20).
This study has confirmed the success of combined
therapy using a fixed dose of RU486 and administering 1 mg
of synthetic PG in pessary form after 48 hours. A similar
success rate for complete abortion would be anticipated with
this PG alone, but at a dosage of 5 x 1 mg pessaries over 12
hours (15,16). Although the administration of PG in this
form may be more acceptable to the patient than
intramuscular injection, the latter route may be preferred
as vaginal drug absorption can be altered in the presence of
bleeding. However, the efficacy of treatment was not
impaired in the present study in which 10 (53%) women had
reported the onset of bleeding prior to pessary insertion.
Most patients experienced some crampy pain during
treatment, but there was no difference between the two
groups in their requirements for analgesics. We have
previously reported a similar requirement using the 16,16-
dimethyl-trans-A2-PGE-j_ methyl ester pessaries alone (17) ;
but in a further group of 30 women undergoing menstrual
induction using the same PG, more patients requested some
form of analgesic: 26 (87%) versus 9 (47%) for the RU486 +
PG group in the present study (P<0.01; I.T. Cameron and D.T.
Baird, unpublished data). Care must be taken in comparing
these results due to the varying subjective awareness of
pain in different populations, varying environmental
factors, and also to differences in the perception of
analgesic requirements on the part of medical and nursing
staff.
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No serious complications were encountered during
therapy, although women in both groups suffered
gastrointestinally-associated side effects. Although some
patients failed to provide adequate pre-treatment data, it
is noteworthy that the incidence of nausea and vomiting did
not alter after the commencement of treatment with RU486,
nor was it significantly affected by the subsequent
administration of PG. Nausea and vomiting are commonly seen
in early pregnancy, but diarrhoea is a more specific PG-
associated problem; this was only seen in 1 case in each
treatment group.
Administration of RU486 was discontinued in 1 woman
after 36 hours because of severe nausea and vomiting which
pre-dated the start of treatment. She subsequently
underwent vacuum aspiration under general anaesthesia
without complication, but this does emphasise the potential
problem of oral drug administration to some women in early
pregnancy.
It has been suggested that in addition to increasing
the complete abortion rate, the effect of RU486 plus PG on
uterine contractility may also reduce the degree of blood
loss (21). In the present study there was no significant
difference in the measured blood loss, and the quantity was
similar to that previously reported following early abortion
with either PG alone or vacuum aspiration (16) and to the
expected menstrual loss during a heavy period (22).
One patient in the RU486 alone group suffered acute
bleeding necessitating uterine evaucation 12 hours later.
Although the bleeding settled with bedrest and a blood
transfusion was not required, such a conservative approach
would not have been clinically acceptable. Although
previous work has outlined the potential danger of excessive
bleeding after RU486 treatment (12), blood loss has not been
objectively documented. Subjective data on the degree of
blood loss between various studies must be interpreted with
caution in the light of the finding that up to 50% of women
with a subjective complaint of menorrhagia will have a
monthly menstrual loss within normal limits (23) . The
duration of blood loss was again similar for the two
treatment groups and did not differ from that seen
previously with either PG- or surgically-induced early
abortion (16).
In conclusion, the antigestogen RU486 provides a safe
method for inducing abortion in early pregnancy with a low
incidence of side effects. When used alone there is an
unacceptably high incomplete or failed abortion rate;
however, the efficacy of treatment approaches that of
standard vacuum aspiration when the drug is administered in
conjunction with a low dose of PG. Although further studies
are required to assess the most appropriate dosage regimens,
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such a combined approach to menstrual induction should offer
an acceptable alternative to surgery for the interruption of
early pregnancy.
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